Podcasts about mrv

In this edition of Plan Sea, hosts Anna Madlener and Wil Burns sit down with Kyla Westphal and Mallory Ringham from Ebb Carbon to discuss Project Macoma — the company's pilot ocean alkalinity enhancement (OAE) study being conducted in Port Angeles, Washington this summer. A first-of-its-kind endeavor, Project Macoma aims to remove up to 1,000 tonnes of  CO2 from the atmosphere using Ebb Carbon's electrochemical OAE technology. Kyla and Mallory join to share more about their journey engaging the local community on this proposed research, securing a permit from the U.S. Environmental Protection Agency (EPA), and establishing Monitoring, Reporting, and Verification (MRV) standards as this work gets underway. Project Macoma continues the work of the late Dr. Matthew Eisaman, Co-Founder of Ebb Carbon and a pivotal figure in the ocean-based carbon dioxide removal (oCDR) field. Matt dedicated his life to fostering a clear understanding of the scientific path forward for potential oCDR solutions, while also creating an inclusive and environmentally-responsible sector. For more background into Ebb Carbon and a deep dive into their approach, listen to our episode with Matt HERE. Kyla Westphal, Vice President of External Affairs at Ebb Carbon, joins Anna and Will to discuss her role developing safe and responsible deployment of OAE. Building on her experience working in what she calls “the intersection between technology and humanity,” Kyla oversees both the stakeholder engagement and ecological safety aspects of Ebb Carbon's work. She shares how Project Macoma is building on years of foundational environmental research and engagement with Washington state regulators, community groups, and tribal governments to earn local buy-in and support. Mallory Ringham, Lead Oceanographer and Head of MRV, then discusses how Ebb Carbon secured the first-ever National Pollutant Discharge Elimination System (NPDES) approval for oCDR under the Clean Water Act. She shares how the permit requires a slow, careful, and continuously monitored operation to ensure water quality standards are met within prescribed mixing zones. Mallory also discusses how Ebb's foundational research created a strong understanding of the seasonal and tidal variability in the region, allowing for more accurate monitoring and analysis of the project. This summer, Mallory will continue to oversee the monitoring process to ensure the project is operating safely, responsibly, and effectively.Plan Sea is a semi-weekly podcast exploring ocean-based climate solutions, brought to you by the Carbon to Sea Initiative & the American University Institute for Responsible Carbon Removal.ACRONYMS / CONCEPTS:MRV (1:05); Monitoring, Reporting and VerificationNPDES (14:56); National Pollutant Discharge Elimination SystemMCDR; Marine Carbon Dioxide Removal  (21:58)Plan Sea is a semi-weekly podcast exploring ocean-based climate solutions, brought to you by the Carbon to Sea Initiative & the American University Institute for Responsible Carbon Removal.

Idiopathic intracranial hypertension (IIH), a condition of increased intracranial pressure (ICP), causes debilitating headaches and, in some, visual loss. The visual defects are often in the periphery and not appreciated by the patient until advanced; therefore, monitoring visual function with serial examinations and visual fields is essential. In this episode, Kait Nevel, MD speaks with John J. Chen, MD, PhD, and Susan P. Mollan, MBChB, PhD, FRCOphth, authors of the article “Treatment and Monitoring of Idiopathic Intracranial Hypertension” in the Continuum® June 2025 Disorders of CSF Dynamics issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Chen is a professor of ophthalmology and neurology at the Mayo Clinic in Rochester, Minnesota. Dr. Mollan is an honorary professor of metabolism and systems science in the department of neuro-ophthalmology at University Hospitals Birmingham in Birmingham, United Kingdom. Additional Resources Read the article: Treatment and Monitoring of Idiopathic Intracranial Hypertension Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @IUneurodocmom Guests: @chenmayo, @DrMollan Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Nevel: Hello, this is Dr Kate Nevel. Today, I'm interviewing Drs John Chen and Susan Mollan about their article on treatment and monitoring of idiopathic intracranial hypertension, which appears in the June 2025 Continuum issue on disorders of CSF dynamics. Drs Chen and Mollan, welcome to the podcast. And please, could you introduce yourselves to the audience? Dr Chen: Hello, everyone. I'm John Chen, one of the neuro-ophthalmologists at the Mayo Clinic. Thanks for having us here. Dr Mollan: Yeah, it's great to be with you here. I'm Susan Mollan. I'm a consultant neuro-ophthalmologist in Birmingham, England. Dr Nevel: Wonderful. So great to have you both here today, and our listeners. To start us off, talking about your article, can you share with us what you think is the most important takeaway from your article for the practicing neurologist out there? Dr Chen: Yeah, so our article talked about the treatment and monitoring of IIH. And I think one takeaway point is, IIH is becoming much more prevalent now that there's this worldwide obesity epidemic with obesity having- essentially being the largest risk factor for IIH other than female. It's really important to monitor vision because vision loss is often peripheral vision loss at first, which the patient may be completely unaware of. And so, it's important to pair up with an ophthalmologist so you can monitor the papilledema of the visual fields and make sure they don't get permanent vision loss. And in the article, we also talk about- there's been changes in the treatment of severe IIH, where traditionally, we used VP shunts; but there's been a trend toward using more venous sinus stenting in addition to the traditional surgeries. Dr Nevel: Great, thank you. I think probably most of our listeners or a lot of neurologists out there have a pretty good understanding of kind of the basics of the IIH. But can you kind of just go over a few key characteristics of IIH, and maybe some things that are less commonly known or things that are maybe just been kind of better understood over the past decade, perhaps? Dr Mollan: Yes, certainly. I think, as Dr Chen said, it's because this condition is becoming more prevalent, people recognize it. I think it's- we like to go back to the diagnostic criteria so that we're making a very accurate diagnosis. So, the patients may come in to the emergency room with, say, papilledema that's been identified elsewhere or crashing headaches. And it's important to go through that sort of diagnostic pathway, taking a blood pressure, taking a full blood count to make sure the patient is anemic, and then moving forward with that confirmation of papilledema into urgent neuroimaging, whether it's CT or MRI, but including venography to exclude a venous sinus thrombosis. And then if you have no structural lesion that's causing the raised ICP, it's moving forward with your lumbar puncture and carefully checking those pressures. But the patients may not only have crashing headache, they often have pulsatile tinnitus and neck pain. I think some of the features that we're now recognizing is the systemic metabolic effects that are unique to IIH. And so, there's an increased risk of cardiometabolic disease that's over and above what is conferred by obesity. Also, our patients have a sort of maternal health burden where they get impaired fertility, gestational diabetes and preeclampsia. And there's also an associated mental health burden, amongst other things. So we're really starting to understand the spectrum of the disease a bit more. Dr Nevel: Yeah, thank you for that. And that really struck me in your article, how important it is to be aware of those things so that we're making sure that we're managing our whole patient and connecting them with the appropriate providers for some of those other issues that may be associated. For the practicing neurologist out there without all the neuro-ophthalmology equipment, if you will, what should our bedside exam focus on to help us get maybe an early but accurate picture of the patient's visual function when we suspect IIH to be at play, perhaps before they can get in with the neuro-ophthalmologist? Dr Chen: Yeah, I think at the bedside you can still check visual acuity and confrontational visual fields, you know, with finger counting. Of course, you have to know that those are, kind of, crude kind of ways of screening. With papilledema, oftentimes the visual acuity is intact. And the confrontational visual fields aren't as sensitive as automated perimetry. Another important thing will be to do your direct ophthalmoscope and look at the amount of papilledema. If it's grade one or two papilledema on the more mild side, it's actually not vision threatening. It's the higher degrees of papilledema that can cause rapid vision loss. And so, if you look in and you see grade one papilledema, obviously you need to do the full workup, the MRI, MRV, lumbar puncture. But in terms of rapidly getting to an ophthalmologist to screen for vision loss, it's not going to be as important because you're not going to have vision loss at that low grade. If you look in and you see this rip-roaring papilledema, grade five papilledema, that patient is going to be at very severe risk of vision loss. So, I think that exam, looking at the optic nerve can be very helpful. And of course, talking to the patient about symptoms; is there decreased vision Is there double vision from a sixth nerve palsy? Are there transient visual obscurations which would indicate at least a higher degree of papilledema? That'd be helpful as well. Dr Nevel: Great, thank you. And when the patient does get in with a neuro-ophthalmologist, you talk in your article and, of course, in clinical practice, how OCT testing is important to monitor in this condition. Can you provide for the listeners the definition of OCT and how it plays a role in monitoring patients with IIH? Dr Mollan: Sure. So, OCT is short for optical coherence tomography imaging, and really the eye has been at the forefront of OCT alone. Our sort of cardiology colleagues are catching up on the imaging of blood vessels. But what it allows us to do is give us really good cross-sectional, anatomical-level changes that we can see both in the retina and also at the optic nerve head. And it gives us some really good measurements. It's not so good at sort of saying, is this definitely papilledema or not? That sort of lower end of disc elevation. But it is very good at ruling out what we call the pseudopapilledema. So, things like drusens or these other little masses we find underneath the optic nerve head. But in terms of monitoring, because we can longitudinally take these images and the reproducibility is pretty good at the optic nerve head, it allows us to see whether there's direct changes: either the papilledema getting worse or the papilledema getting better at the optic nerve head. It also gives us some indication of what's going on in the ganglion cell layer complex. And that can be helpful when we're thinking about sort of looking at structure versus function. So, ophthalmologists in general, we love OCT; and we spend much more time nowadays looking at the OCT than we really do the back of the eye. And it's just become critical for patients with papilledema to be able to be very accurate from visit to visit to see what's changing. Dr Nevel: How do you determine how frequently somebody needs to see the neuro-ophthalmologist with IIH and how often they need that OCT evaluation? Dr Chen: Once the diagnosis of IIH is made, how often they need to be seen and how frequent they need to be seen depends on the degree of papilledema. And again, OCT is really nice. You can quantify it and then different providers can actually use the same OCT numbers, which is super helpful. But again, if it's grade three papilledema or higher, or article thickness of 200 or higher, I tend to follow them a little bit more closely, trying to treat them more aggressively. Try to get the papilledema down into a safer zone. If it's grade one or two papilledema, we see them less frequently. So, my first visit might be three months out. They come with grade five papilledema, I'm seeing them within a few days to make sure that's papilledema's come down quickly because we're trying to decide, are they going to need surgery or not? Dr Nevel: Yeah, great. And that's a nice segue into talking a little bit about how we treat patients with IIH after the diagnosis is confirmed. And I'd like to just point out you have a very lovely figure in your article---Figure 5-6,---that I'd like to direct our listeners to read your article and check out that figure, which is kind of an algorithm on how we think about the various treatment options for patients who have IIH, which seems to rely a lot on the degree of presence of papilledema and the presence of vision disturbance. Could you maybe walk us through a little bit about how you think about the different treatment options for patients with IIH and when more urgent surgical intervention might be indicated? Dr Mollan: Yeah, sure. We always find it quite hard in any medical specialty to write these kind of flow diagrams because it's really an individual we're looking at. But these are kind of what we'd say is “broad brushstrokes” into those patients that we worry about, sort of, red disease in those patients, more amber disease. Now obviously, even those patients that may not have severe papilledema, they may have crashing headaches. So, they may be an urgent referral themselves because of that. And so, it's nice to try and work out which end of the spectrum you're working with. If we think of the papilledema, Dr Chen's already laid out the sort of lower end of the prison's scale---our grades one, our grades two---that we're less anxious about. And those patients, we would definitely be having discussions about medical management, which includes acetazolamide therapy; but also thinking about weight management. And it may well be that we talk a little bit further about weight management, but I think it's helpful to sort of coach those conversations after you've made a definite diagnosis. And then laying out the risk that's caused, potentially, the IIH in an individual. And then having a sort of open conversation with them about what changes they can have in their lifestyle alongside thinking about medical therapy. There's some patients with very low levels of papilledema that we decide not to put on medicines initially. As patients progress up that papilledema grade, we're definitely thinking about medical therapy. And our first line from the IIH treatment trial would be using acetazolamide, but we need to be thinking about using appropriate dosing. So, a lot of the patients that I see can be sent to me with very low doses that may be inappropriate for that person. In the IIHTT they used up to four grams daily in a divided dose. And you do need to counsel your patients when you're putting them on acetazolamide because of the side effects. You've got quite a nice table in this article about the side effects. I think if you get the patient on board, that they understand that they will experience side effects, that is helpful because they will expect it, and then possibly tolerate it a bit better. Moving through to that area where we're more anxious, that visual-threatening papilledema. As Dr Chen said, it's sort of like you look in and it's sort of “blood and thunder” in there. And you need to be getting on and encouraging the ophthalmologist to get a formal assessment of the visual field. It's very difficult to determine exactly the level at which- and we talk about the mean deviation in a lot of our research studies. But in general, it's a combination of things: the patient's journey to get to you, their symptoms, what's going on with the visual field, but what's also happening at the OCT. So, we look in and we see that fluid is seeping towards the fovea. We get very anxious, and those patients may not even have enough time for a rapid escalation of acetazolamide. It may well be at the first presentation, which we would term, like, fulminant; that we'd be thinking about surgical intervention. And I think before I stop, the other thing to say is, the surgical landscape is really changing. So, we're having some good studies coming out in terms of stenting. And so, there is a sort of bracket where it may well be that we are thinking about neuroradiological intervention in an earlier case. They may not quite be at that visual-threatening stage, but they may be resistant to medical treatments. Dr Nevel: Thank you for that. What do you think is a potential pitfall or a mistake to avoid, if you will, in the management of patients with IIH? Dr Chen: I think it's- in terms of pitfalls, I think the potential pitfalls I've seen are essentially patients where we don't necessarily create a good patient physician relationship. Where they don't have buy-ins on the treatment, they don't have buy-ins to come back, and they're lost to follow-up. And these patients can be dangerous, because they could have vision threatening papilledema and if not getting the appropriate treatment---and if they're not monitoring the vision---this can lead to poor outcomes. So, I've definitely seen that happen. As Dr Mollan said, you really have to tell them about the side effects from the medications. If you just take acetazolamide, letting them know the paresthesias and the changes in taste and some of these other side effects, they're going to immediately stop the medication. Again, and these medications do work, proven in the IIH treatment trial. So again, I think that patient-physician relationship is very important to make sure they have appropriate follow up. Dr Nevel: The topic of weight loss in this patient population can be tricky, and I know I talked with Susie in a prior interview about how to approach this topic with our patients in a sensitive and compassionate manner. Once this topic is broached, I find many patients are looking for advice on strategies for weight loss, or potentially medications or other interventions. How do you prioritize or think about the different weight loss strategies or treatments with your patients, and how do you think about the way that you recommend these different treatments or not? Dr Mollan: Yeah. I think that's a really great question because we sort of stray here into a specialty that we have not been trained in. One thing I definitely ask my patients: if they've been on a weight loss journey before, and what's worked for them and what's not worked for them. And within our different healthcare systems, we have access to different tiers of weight management approaches. But for the person sitting in front of me, that possibly there may be a long journey to access more professional care, it's about understanding. iIs there things that are free, such as, we have some apps in the National Health Service which are weight management applications where they can actually just start putting in their calories, their daily calorie intake. And those apps can be quite helpful and guiding in terms of targeting areas, but also informing the patient of what types of foods to avoid in their diet and what types of foods to include in their diet. And with some of the programs that are completely complementary, they also sometimes add on things about exercise. But I think it is a really difficult thing to manage as, say, an ophthalmologist or a neurologist, mainly because it's not our area of expertise. And I think we've all got to find, in our local hospitals and healthcare systems, those pathways where the patients may be able to access nutritional support, and sort of behavioral lifestyle therapy support, all the way through to the new medications for weight loss; and also for some people, bariatric surgery pathways. It's a tricky topic. Dr Nevel: So how should we counsel our patients about what to expect in the future in terms of visual outcomes? Dr Chen: I think a lot of that depends on the degree of papilledema when they present. If a patient comes in with grade five papilledema, that fulminant IIH that Dr Mollan had mentioned, these patients can have very severe vision loss. And even if we treat them very aggressively with high-dose medications and urgent surgical interventions, sometimes they can have permanent vision loss. And so, we counsel them that, you know, there's a strong chance that they're going to have a good amount of vision loss. But some patients, we're very surprised and we get a lot of vision back. So, we kind of set expectations, but we're cautiously optimistic that we can get vision back. If a patient presents with more mild papilledema like grade one or two papilledema, they're most likely not going to have any permanent vision loss as long as we're treating them, we're monitoring their vision, they're coming to their follow-ups. They tend to do very well from a vision perspective. Dr Nevel: That's great, thank you. And you know, ties into what you said earlier about really making sure that, you know, we create good- as with any patient, but good physician-patient relationships so that they, you know, trust us and they come to follow up so we can really monitor their vision appropriately. What do you think is going on in research in this area that's exciting? What do you think one of the next breakthroughs or thing that we need to understand the most about treatment and monitoring of IIH? Dr Chen: I think surgically, venous sinus stenting is going to probably take over the bulk of surgeries. We still need that randomized clinical trial, but we have some amazing outcomes with venous sinus stenting. And there's many efforts on randomized clinical trials for venous sinus stenting. So we'll have those results soon. From a medical standpoint, Dr Mollan can actually say, actually, more about this. Dr Mollan: I completely agree. The GLP-1 receptor agonists, the twofold prong approach: one is the weight loss where these patients, you know, have significant weight loss to put their disease into remission; and the other side of it is whether certain GLP-1s have the ability to reduce intracranial pressure. So, a phase 2 study that we undertook here in Birmingham did show that we were able to reduce intracranial pressure, but we don't think it's a class effect. So, I think the sort of big breakthrough will be looking at novel therapies like xenotide and other drugs that, say, work on the proximal kidney tubule. Are they able to reduce intracranial pressure directly? And I think we are on the cusp of a real breakthrough for this disease. Dr Nevel: Great. Thank you so much for chatting with me today. And I really learned a lot, appreciated the opportunity. I hope our listeners learned something today, too. So again, today I've been interviewing Drs John Chen and Susan Mollan about their article on treatment and monitoring of idiopathic intracranial hypertension, which appears in the most recent issue of Continuum on disorders of CSF dynamics. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining us today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

O mercado de médio padrão vive um momento aquecido — e os corretores precisam estar prontos para aproveitar as oportunidades. Falamos sobre a entrada de novos perfis no Minha Casa Minha Vida, o impacto da alta do metro quadrado, a diversificação de produtos e as principais tendências que vêm moldando os lançamentos no segmento. Também abordamos estratégias de venda, posicionamento e como criar uma comunicação eficaz nesse nicho, mesmo que ele ainda não seja o seu principal foco.Neste episódio, recebemos Pricilla Alves (@pricillaalves), Gerente de Produto e Gerente de Trade Marketing na MRV&CO, e Bárbara Martins (@barbarapmm), Gerente Regional de Vendas, para compartilhar experiências práticas e insights valiosos sobre o crescimento do médio padrão — e o papel estratégico do corretor nesse cenário em transformação.

O episódio do Podcast VendaMais é uma verdadeira aula sobre liderança comercial em ambientes complexos.Marcelo Caetano recebe Thiago Ely, VP Comercial e de Marketing da MRV.Neste papo direto e cheio de aprendizados, você vai descobrir:✔ Como liderar times que lidam com milhares de leads por mês;✔ Por que o sucesso comercial começa no desenvolvimento de produto;✔ O papel real da IA na gestão de funil (e o que ela ainda não resolve);✔ Como alinhar processos, produto e pessoas em alta performance;✔ Por que testar, ajustar e ouvir o cliente são decisões de liderança (não só da ponta).Se você lidera um time comercial, vive o desafio de escalar com consistência e quer estratégias de quem realmente vive isso na prática — esse episódio é pra você.Dá o play e vem com a gente!

Idiopathic intracranial hypertension (IIH) is characterized by symptoms and signs of unexplained elevated intracranial pressure (ICP) in an alert and awake patient. The condition has potentially devastating effects on vision, headache burden, increased cardiovascular disease risk, sleep disturbance, and depression.  In this episode, Teshamae Monteith, MD, FAAN speaks with Aileen A. Antonio, MD, FAAN, author of the article “Clinical Features and Diagnosis of Idiopathic Intracranial Hypertension” in the Continuum® June 2025 Disorders of CSF Dynamics issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Antonio is an associate program director of the Hauenstein Neurosciences Residency Program at Trinity Health Grand Rapids and an assistant clinical professor at the Michigan State University College of Osteopathic Medicine in Lansang, Michigan. Additional Resources Read the article: Clinical Features and Diagnosis of Idiopathic Intracranial Hypertension Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Guest: @aiee_antonio Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Monteith: Hi, this is Dr Teshamae Monteith. Today I'm interviewing Dr Aileen Antonio about her article on clinical features and diagnosis of idiopathic intracranial hypertension, which appears in the June 2025 Continuum issue on disorders of CSF dynamics.  Hi, how are you? Dr Antonio: Hi, good afternoon. Dr Monteith: Thank you for being on the podcast. Dr Antonio: Thank you for inviting me, and it's such an honor to write for the Continuum. Dr Monteith: So why don't you start off with introducing yourself? Dr Antonio: So as mentioned, I'm Aileen Antonio. I am a neuro-ophthalmologist, dually trained in both ophthalmology and neurology. I'm practicing in Grand Rapids, Michigan Trinity Health, and I'm also the associate program director for our neurology residency program. Dr Monteith: So, it sounds like the residents get a lot of neuro-ophthalmology by chance in your curriculum. Dr Antonio: For sure. They do get fed that a lot. Dr Monteith: So why don't you tell me what the objective of your article was? Dr Antonio: Yes. So idiopathic intracranial hypertension, or IIH, is a condition where there's increased intracranial pressure, but without an obvious cause. And with this article, we want our readers---and our listeners right now---to recognize that the typical symptoms and learning about the IIH diagnostic criteria are key to avoiding errors, overdiagnosis, or sometimes even misdiagnosis or underdiagnosis. Thus, we help make the most of our healthcare resources. Early diagnosis and management are crucial to prevent disability from intractable headaches or even vision loss, and it's also important to know when to refer the patients to the appropriate specialists early on. Dr Monteith: So, it sounds like your central points are really getting that diagnosis early and managing the patients and knowing how to triage patients to reduce morbidity and complications. Is that correct? Dr Antonio: That is correct and very succinct, yes. Dr Monteith: And so, are there any more recent advances in the diagnosis of IIH? Dr Antonio: Yes. And one of the tools that we've been using is what we call the optical coherence tomography. A lot of people, neurologists, physicians, PCP, ER doctors; how many among those physicians are well-versed in doing an eye exam, looking at the optic disc? And this is a great tool because it is noninvasive, it is high resolution imaging technique that allows us to look at the optic nerve without even dilating the eye. And we can measure that retinal nerve fiber layer, or RNFL; and that helps us quantify the swelling that is visible or inherent in that optic nerve. And we can even follow that and monitor that over time. So, this gives us another way of looking at their vision and getting that insight as to how healthy is their vision still, along with the other formal visual tests that we do, including perimetry or visual field testing. And then all of these help in catching potentially early changes, early worsening, that may happen; and then we can intervene more easily. Dr Monteith: Great. So, it sounds like there's a lot of benefits to this newer technology for our patients. Dr Antonio: That is correct. Dr Monteith: So, I read in the article about the increased incidence of IIH, and I have to say that I completely agree with you because I'm seeing so much of it in my clinic, even as a headache specialist. And I had a talk with a colleague who said that the incidence of SIH and IIH are similar. And I was like, there's no way. Because I see, I can see several people with IIH just in one day. That's not uncommon. So, tell me what your thoughts are on the incidence, the rising incidence of IIH; and we understand that it's the condition associated with obesity, but it sounds like you have some other underlying drivers of this problem. Dr Antonio: Yes, that is correct. So, as you mentioned, IIH tends to affect women of childbearing age with obesity. And it's interesting because as you've seen that trend, we see more of these IIH cases recently, which seem to correlate with that rising rate of obesity. And the other thing, too, is that this trend can readily add to the burden of managing IIH, because not only are we dealing with the headaches or the potential loss of vision, but also it adds to the burden of healthcare costs because of the other potential comorbidities that may come with it, like cardiovascular risk factors, PCOS, and sleep apnea. Dr Monteith: So why don't we just talk about the diagnosis of IIH? Dr Antonio: IIH, idiopathic intracranial hypertension, is also called pseudotumor cerebri.  It's essentially a condition where a person experiences increased intracranial pressure, but without any obvious cause. And the tricky part is that the patients, they're usually fully awake and alert. So, there's no obvious tumor, brain tumor or injury that causes the increased ICP. It's really, really important to rule out other conditions that might cause these similar symptoms; again, like brain tumors or even the cerebral venous sinus thrombosis. Many patients will have headaches or visual disturbances like transient visual obscurations---we call them TVOs---or double vision or diplopia. The diplopia is usually related to a sixth nerve palsy or an abducens palsy. Some may also experience some back pain or what we call pulsatile tinnitus, which is that pulse synchronous ringing in their ears. The biggest sign that we see in the clinic would be that papilledema; and papilledema is a term that we only use, specifically use, for those optic nerve edema changes that is only associated with increased intracranial pressure. So, performing of endoscopy and good eye exam is crucial in these patients. We usually use the modified Dandy criteria to diagnose IIH. And again, I cannot emphasize too much that it's really important to rule out other secondary causes to that increased intracranial pressure. So, after that thorough neurologic and eye evaluation with neuroimaging, we do a lumbar puncture to measure the opening pressure and to analyze the cerebrospinal fluid. Dr Monteith: One thing I learned from your article, really just kind of seeing all of the symptoms that you mentioned, the radicular pain, but also- and I think I've seen some papers on this, the cognitive dysfunction associated with IIH. So, it's a broader symptom complex I think than people realize. Dr Antonio: That is correct. Dr Monteith: So, you mentioned TVOs. Tell me, you know, if I was a patient, how would you try and elicit that from me? Dr Antonio: So, I would usually just ask the patient, while you're sitting down just watching TV---some of my patients are even driving as this happens---they would suddenly have these episodes of blacking out of vision, graying out of vision, vision loss, or blurred vision that would just happen, from seconds to less than a minute, usually. And they can happen in one eye or the other eye or both eyes, and even multiple times a day. I had a patient, it was happening 50 times a day for her. It's important to note that there is no pain associated with it most of the time. The other thing too is that it's different from the aura that patients with migraines would have, because those auras are usually scintillating and would have what we call the positive phenomena: the flashing lights, the iridescence, and even the fortification that they see in their vision. So definitely TVOs are not the migraine auras. Sometimes the TVOs can also be triggered by sudden changes in head positions or even a change in posture, like standing up quickly. The difference, though, between that and, like, the graying out of vision or the tunneling vision associated with orthostatic hypotension, is that the orthostatic hypotension would also have that feeling of lightheadedness and dizziness that would come with it. Dr Monteith: Great. So, if someone feels lightheaded, less likely to be a TVO if they're bending down and they have that grain of vision. Dr Antonio: That is correct. Dr Monteith: Definitely see patients like that in clinic. And if they have fluoride IIH, I'm like, I'll call it a TVO; if they don't, I'm like, it's probably more likely to be dizziness-related. And then we also have patient migraines that have blurriness that's nonspecific, not necessarily associated with aura. But I think in those patients, it's usually not seconds long, it's usually probably longer episodes of blurriness. Would you agree there, or…? Dr Antonio: I would agree there, and usually the visual aura would precede the headache that is very characteristic of their migraine, very stereotypical for their migraines. And then it would dissipate slowly over time as well. With TVOs, they're brisk and would not last, usually, more than a minute. Dr Monteith: So, why don't we talk about routine imaging? Obviously, ordering an MRI, and I read also getting an MRV is important. Dr Antonio: It is very important because, one: I would say IIH is also a diagnosis of exclusion. We need to make sure that the increased ICP is not because of a brain tumor or not because of cerebral venous sinus thrombosis. So, it's important to get the MRI of the brain as well as the MRV of the head. Dr Monteith: Do you do that for all patients' MRV, and how often do you add on an orbital study? Dr Antonio: I usually do not add on an orbital study because it's not really going to change my management at that point. I really get that MRI of the brain. Now the MRV, for most of my patients, I would order it already just because the population that I see, I don't want to lose them. And sometimes it's that follow-up, and that is the difficult part; and it's an easy add on to the study that I'm going to order. Again, it depends with the patient population that you have as well, and of course the other symptoms that may come with it. Dr Monteith: So, why don't we talk a little bit about CSF reading and how these set values, because we get people that have readings of 250 millimeters of water quite frequently and very nonspecific, questionable IIH. And so, talk to me about the set value. Dr Antonio: Right. So, the modified Dandy criteria has shown that, again, we consider intracranial pressure to be elevated for adults if it's above 250 millimeters water; and then for kids if it's above 280 millimeters of water. Knowing that these are taken in the left lateral decubitus position, and assuming also that the patients were awake and not sedated during the measurement of the CSF pressure. The important thing to know about that is, sometimes when we get LPs under fluoroscopy or under sedation, then these can cause false elevation because of the hypercapnia that elevated carbon dioxide, and then the hypoventilation that happens when a patient is under sedation. Dr Monteith: You know, sometimes you see people with opening pressures a little bit higher than 25 and they're asymptomatic. Well, the problem with these opening pressure values is that they can vary somewhat even across the day. People around 25, you can be normal, have no symptoms, and have opening pressure around 25- or 250; and so, I'm just asking about your approach to the CSF values. Dr Antonio: So again, at the end of the day, what's important is putting everything together. It's the gestalt of how we look at the patient. I actually had an attending tell me that there is no patient that read the medical textbook. So, the, the important thing, again, is putting everything together. And what I've also seen is that some patients would tell me, oh, I had an opening pressure of 50. Does that mean I'm in a dire situation? And they're so worried and they just attach to numbers. And for me, what's important would be, what are your symptoms? Is your headache, right, really bad, intractable? Number two: are you losing vision, or are you at that cusp where your optic nerve swelling or papilledema is so severe that it may soon lead to vision loss? So, putting all of these together and then getting the neuroimaging, getting the LP. I tell my residents it's like icing on the cake. We know already what we're dealing with, but then when we get that confirmation of that number… and sometimes it's borderline, but this is the art of neurology. This is the art of medicine and putting everything together and making sure that we care and manage it accordingly. Dr Monteith: Let's talk a little bit about IIH without papilledema. Dr Antonio: So, let's backtrack. So, when a patient will fit most of the modified Dandy criteria for IIH, but they don't have the papilledema or they don't have abducens palsy, the diagnosis then becomes tricky. And in these kinds of cases, Dr Friedman and her colleagues, when they did research on this, suggested that we might consider the diagnosis of IIH. And she calls this idiopathic intracranial hypertension without papilledema, IIHWOP. They say that if they meet the other criteria for modified Dandy but show at least three typical findings on MRI---so that flattening of the posterior globe, the tortuosity of the optic nerves, the empty sella or the partially empty sella, and even the narrowing of the transverse venous sinuses---so if you have three of these, then potentially you can call these cases as idiopathic intracranial hypertension without papilledema. Dr Monteith: Plus, the opening pressure elevation. I think that's key, right? Getting that as well. Dr Antonio: Yes. Sometimes IIHWOP may still be a gray area. It's a debate even among neuro-ophthalmologists, and I bet even among the headache specialists. Dr Monteith: Well, I know that I've had some of these conversations, and it's clear that people think this is very much overdiagnosed. So, that's why I wanted to plug in the LP with that as well. Dr Antonio: Right. And again, we have not seen yet whether is, this a spectrum, right? Of that same disease just manifesting differently, or are they just sharing a same pathway and then diverging? But what I want to emphasize also is that the treatment trials that we've had for IIH do not include IIHWOP patients. Dr Monteith: That is an important one. So why don't you wrap this up and tell our listeners what you want them to know? Now's the time. Dr Antonio: So, the- again, with IIH, with idiopathic intracranial hypertension, what is important is that we diagnose these patients early. And I think that some of the issues that come into play in dealing with these patients with IIH is that, one: we may have anchoring bias. Just because we see a female with obesity, of reproductive age, with intractable headaches, it does not always mean that what we're dealing with is IIH. The other thing, too, is that your tools are already available to you in your clinic in diagnosing IIH, short of the opening pressure when you get the lumbar puncture. And I need to emphasize the importance of doing your own fundoscopy and looking for that papilledema in these patients who present to you with intractable headaches or abducens palsy. What I want people to remember is that idiopathic intracranial hypertension is not optic nerve sheath distension. So, these are the stuff that you see on neuroimaging incidentally, not because you sent them, because they have papilledema, or because they have new headaches and other symptoms like that. And the important thing is doing your exam and looking at your patients. Dr Monteith: Today, I've been interviewing Dr Aileen Antonio about her article on clinical features and diagnosis of idiopathic intracranial hypertension, which appears in the most recent issue of Continuum on disorders of CSF dynamics. Be sure to check out Continuum Audio episodes from this and other issues, and thank you to our listeners for joining today. Thank you again. Dr Antonio: Thank you. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

This isn't planting trees—it's a return to the wisdom we clear-cut away. This episode delves into how Chestnut Carbon has raised $160 million to transform degraded land into climate-positive assets, reimagining carbon credits from the ground up. By buying land outright, restoring native forests, and building trust with enterprise buyers like Microsoft, Chestnut Carbon is proving that nature-based solutions can be credible, scalable, and wildly effective.

O que diferencia os corretores que conseguem se manter em alta no mercado daqueles que desistem no meio do caminho? Neste episódio, exploramos os bastidores da jornada de quem construiu uma carreira sólida com foco, disciplina e consistência. Falamos sobre frustração, viradas de chave, estratégias que realmente funcionam, e como lidar com a rotina sem perder o fôlego – mesmo quando o cliente diz “não”.Neste episódio, recebemos Rui Petterson (@ruipetterson) e Fernando Cesarino (@fernando_rodrigo_cesarino), corretores de imóveis parceiros da MRV, para compartilhar suas histórias inspiradoras, aprendizados da prática e os segredos que os ajudam a crescer de forma sustentável — com a mentalidade e os resultados de um verdadeiro corretor de milhões.

In this edition of Plan Sea, host Anna Madlener is joined by Na'im Merchant, host of The Carbon Curve podcast and Executive Director of Carbon Removal Canada, for a special co-hosted episode of the two podcasts. Recorded live at the Carbon to Sea 2025 Annual Convening, Anna and Na'im speak with Lennart Bach, Associate Professor and ocean alkalinity enhancement (OAE) scientist at the University of Tasmania, to share insights and key takeaways from this year's convening.Last month, Carbon to Sea hosted its third Annual Convening in Washington, D.C., bringing together scientists, entrepreneurs, and policymakers to share recent progress and discuss a path forward for OAE. Bach, who previously spoke with Plan Sea on his work in ocean iron fertilization, was a speaker on this year's “Scientific Research Progress and Updates” panel. Focused on the environmental impacts of OAE, Bach's research aims to learn more about how OAE approaches may impact the marine ecosystem.Building on conversations from the convening, Bach joins Anna and Na'im to share his optimism about the future of OAE, while also recognizing the potential challenges posed by a dip in the “hype cycle” that emerging scientific fields often face. However, Bach said he feels confident in progress that's already been made and noted the importance of building on preliminary findings about OAE's potential to conduct more targeted research. Na'im similarly addresses this challenging moment for the climate industry writ large, as it faces reduced funding and policy support in many areas, with new geopolitical headwinds. Drawing on his experience working across the carbon removal space, Na'im offers advice for how the OAE field can address this moment by prioritizing focused research, establishing an updated roadmap, and exploring new funding pathways. Looking ahead, both Na'im and Bach highlight the importance of aligning on MRV approaches, cross-sector partnerships, increased community and policymaker engagement, and exploring new funding pathways in order to advance OAE research. As this year's convening exemplified, the immediate opportunities in OAE research have largely been addressed; what lies ahead is more complex and demands significantly greater coordination.Listen to our previous episode with Lennart Bach here.ACRONYMS / CONCEPTS: OAE (2:28)MRV (18:06)DAC (23:37)CRCF (29:59)ETS (29:59)ERW (36:16)Plan Sea is a semi-weekly podcast exploring ocean-based climate solutions, brought to you by the Carbon to Sea Initiative & the American University Institute for Responsible Carbon Removal.

Episode 52 is a special joint episode with Plan Sea host Anna Madlener and Lennart Bach, Associate Professor and ocean alkalinity enhancement (OAE) scientist at the University of Tasmania.In this episode, Na'im joins Anna Madlener for a special co-hosted episode between Plan Sea and The Carbon Curve, recorded live at the Carbon to Sea 2025 Annual Convening. Anna and Na'im speak with Lennart Bach, to share insights and key takeaways from this year's convening.Last month, Carbon to Sea hosted its third Annual Convening in Washington, D.C., bringing together scientists, entrepreneurs, and policymakers to share recent progress and discuss a path forward for OAE. Building on the conversations started during the convening, Na'im and Bach highlight the importance of aligning on MRV approaches, cross-sector partnerships, increased community and policymaker engagement, and new funding pathways as key avenues to explore. Na'im Merchant is the co-founder and Executive Director of Carbon Removal Canada, a policy initiative focused on scaling carbon removal in Canada. He was a policy fellow with Elemental Impact. He previously ran carbon removal consulting practice Carbon Curve, and publishes The Carbon Curve newsletter and podcast. This post represents his personal views and not those of Carbon Removal Canada. You can get in touch with him on LinkedIn. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit carboncurve.substack.com

Com a chegada da Faixa 4 e a ampliação dos tetos de renda nas faixas já existentes, o programa Minha Casa, Minha Vida passou por mudanças importantes que impactam diretamente o mercado — e abrem novas portas para o corretor de imóveis. Saber como essas atualizações afetam o acesso ao crédito, os tipos de imóveis ofertados e o perfil dos clientes é essencial para se posicionar como um especialista e sair na frente na hora de fechar negócios.Neste episódio, recebemos Dora Magalhães (@mge_correspondente), correspondente CAIXA AQUI! com 45 anos de experiência no mercado imobiliário, e Alex Atanazio (@alexatanazio1), coordenador de crédito imobiliário na MRV para ajudar corretores a aproveitarem ao máximo o novo momento do programa.

O trabalho filantrópico é um dos objetivos da construtora MRV, que criou, em 2014, um instituto com objetivo de promover transformações sociais por meio de programas educacionais para crianças, jovens e até os educadores.Há mais de 10 anos o Instituto MRV já beneficiou mais de 2,8 milhões de pessoas, considerando o impacto direto e indireto das ações. Os investimentos acumulados da instituição ultrapassam R$48 milhões.As ações do Instituto estão organizadas em quatro pilares:MRV Voluntários: ação que envolve colaboradores da empresa em atividades sociais.Educar para Transformar: que fortalece organizações da sociedade civil por meio do apoio a projetos educacionais. Somente no ano de 2024, dez projetos foram contemplados pela ação.Seu Filho, Nosso Futuro: busca apoiar a educação dos filhos de funcionários da MRV. A ação já beneficiou mais de 40 mil crianças desde 2017 e conta com investimento de R$ 4,4 milhões.Instituto Iungo: é uma ação voltada para educadores, promove a formação continuada dos beneficiados a partir do desenvolvimento de materiais pedagógicos e parcerias com redes públicas de ensino.Para falar mais sobre as ações do Instituto MRV e a importância de grandes empresas, como a construtora, na promoção de trabalhos filantrópicos e sociais, o Observatório Feminino deste domingo (4), recebe Maria Fernanda Menin, presidente do Instituto MRV. Além de presidente, Maria Fernanda é membro do Conselho de Administração da Inter&Co e do Banco Inter.

In this powerful and perspective-shifting episode of Performance Talk, host Dr. Ewell Gordon welcomes Dr. Mike Israetel—renowned sports scientist, professor, co-founder of Renaissance Periodization, and competitive athlete. From high school wrestling roots to academic mastery in performance science, Mike shares his journey through education, self-discovery, and relentless pursuit of truth in training. Gain insider insights on the evolution of strength and conditioning, the misconceptions of overtraining, and why recovery is the unsung hero of peak performance. The conversation dives into the modern athlete's toolkit—from high school weight rooms to AI-powered programming—and challenges long-held myths in sport and fitness culture. Key Takeaways: Smart Training > Hard Training: Understanding maximum recoverable volume (MRV) is essential—more isn't always better. Recovery is a Performance Tool: The best athletes train hard and recover smarter than their competition. Evolving Knowledge: What worked 10–20 years ago might not be optimal today. Science helps us refine our approach. Academic Curiosity Fuels Great Coaching: Seeking evidence and asking “why” drives better long-term results than blind tradition. Information Overload is Real: In today's digital age, athletes must be critical thinkers when filtering training advice. Mental Toughness ≠ Mindless Drills: Purpose-driven programming beats “just grind” culture for long-term development. Tech Meets Intuition: Even with AI and apps, lived athletic experience still plays a critical role in program design.

Nem todo começo é fácil — e no mercado imobiliário, isso é ainda mais verdade. Neste episódio, falamos sobre os desafios do início na corretagem, momentos de dúvida, aprendizados e o que realmente fez a diferença para seguir em frente. Uma conversa leve, honesta e cheia de identificação pra quem vive (ou quer viver) de vender imóveis.Recebemos Debora Costa (@deborascosta_oficial), da Viver Bem Imóveis, e Caroline Souza (@caroline_corretoraa), corretora parceira da MRV. Elas compartilharam experiências, inseguranças, conquistas e a importância da conexão no atendimento ao cliente.

Wevertonn Costa, profissional com 28 anos de experiência em vendas e 13 no mercado imobiliário, com passagens por Ambev, Gafisa, MRV, Tenda e atualmente na liderança comercial da Plano & Plano. Wevertonn conta como a incorporadora, que saiu de R$ 900 milhões em vendas em 2020 para quase R$ 4 bilhões em 2024, graças a uma estratégia focada em encantamento no ponto de venda, uso intensivo de CRM e marketing digital, além da construção de uma rede com 20 pontos de atendimento em São Paulo.Ele também compartilha sua visão de liderança, baseada na formação de times de alta performance, investimento em houses próprias e desenvolvimento de gestores por meio do projeto “Gestor Eficiente”. Além da carreira, falamos sobre suas paixões pela música e pelos cavalos, e ele deixou conselhos poderosos sobre ética, visão de longo prazo e como alcançar o sucesso com consistência e método._____Corretor de imóveis, a Plano&Plano tem um convite para você. Venha trabalhar em uma das Houses Plano&Plano: >> ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/corretor23⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠_____Missão Alto Padrão & Luxo - a principal imersão em imóveis de alto padrão de luxo do país. Inscrições abertas: >> ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.missaoaltopadrao.com.br⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠_____Siga o ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@vempramesapodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ e ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@sergiolanger⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ no instagram.           _____Acompanhe o Vem pra mesa no YouTube: >> ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/sergiolanger

Der Maßregelvollzug in Deutschland steckt in einer tiefen Krise: Überbelegte Kliniken, Personalmangel und Patienten, die oft jahrelang keine Perspektive auf Entlassung haben. In dieser Folge befassen wir uns mit einem Aspekt des MRV, der uns sehr am Herzen liegt: Die seit Jahren anhaltende Überbelegung der Maßregelvollzugseinrichtungen in Deutschland. Neben dieser Diskussion sprechen wir außerdem über den Mord an einer jungen Frau im Jahr 2023, der durch einen Patienten einer forensisch-psychiatrischen Klinik begangen wurde. Wir sprechen darüber, wie es dazu kommen konnte, fragen uns, welche Rolle die Überlastung des MRV dabei spielte und ob diese schreckliche Tat hätte verhindert werden können? #blackbox #psycrime #maßregelvollzugHier bekommt ihr alle Infos zu unseren Werbepartnern: https://linktr.ee/blackbox_psycrime Hosted on Acast. See acast.com/privacy for more information.

As novas regras do Minha Casa Minha Vida representam um desafio para os corretores ou uma grande oportunidade de crescimento? Como se adaptar e aproveitar ao máximo essas mudanças?Para responder a essas perguntas, recebemos Felipe Queiroz (@felipe.queirozoficial) e Marcela Drummond (@marceladrummond), corretores de imóveis parceiros da MRV. Com experiência prática, eles compartilham dicas valiosas sobre crédito imobiliário, qualificação de clientes e gestão de carteira.

EsKanguro, una startup barcelonesa que ha revolucionado la logística de última milla mediante el uso de inteligencia artificial (IA). Recientemente, la empresa cerró una ronda de financiación de 2 millones de euros, con el objetivo de expandirse internacionalmente (Portugal, Francia y Alemania) y seguir desarrollando su tecnología. Kanguro fue fundada en 2021 por Xavi Valverde, César Valencia e Iván Lorca, emprendedores con experiencia en otros proyectos tecnológicos, incluyendo PlayGiga, adquirida por Facebook. La startup surgió al identificar las ineficiencias en las entregas a domicilio, que se intensificaron con el auge del e-commerce durante la pandemia. La propuesta de Kanguro se basa en un ecosistema de IA que optimiza los procesos logísticos mediante el uso de agentes inteligentes. En lugar de depender de entregas individuales en domicilios, apuestan por un modelo de recogida en puntos de conveniencia (PUDOS), con más de 5.000 puntos en España y expansión en Portugal. Esto permite reducir entregas fallidas, optimizar rutas y mejorar la eficiencia del sector. En los últimos tres meses, Kanguro ha experimentado un crecimiento del 200% en facturación en España. Además, ha cerrado acuerdos con grandes operadores logísticos como UPS, Amazon, MRV y On Time, lo que le ha permitido gestionar decenas de miles de entregas diarias. Actualmente, más del 60% de los envíos en España se realizan a través de sus operadores aliados. Iván Lorca, Cofundador de Kanguro ha señalado que el modelo tradicional de entregas domiciliarias está en declive, debido a la falta de repartidores y furgonetas suficientes para atender la creciente demanda. La solución pasa por un cambio de hábitos del consumidor, fomentando la recogida en puntos cercanos en lugar de esperar en casa. El uso de inteligencia artificial ha sido clave para la expansión rápida de la red de puntos de recogida, reduciendo la necesidad de recursos humanos adicionales y permitiendo la automatización y escalabilidad del servicio. Kanguro también apuesta por la sostenibilidad, ya que su modelo de consolidación de envíos reduce significativamente las emisiones de CO₂ en comparación con las entregas individuales. Están analizando datos para medir su impacto ambiental de forma tangible.ta mañana nos acompaña una compañía que tiene su origen en Barcelona.

A inteligência artificial chegou para transformar o mercado imobiliário, e quem souber usá-la estará sempre um passo à frente. Quer descobrir como tirar o melhor proveito dessa tecnologia e surpreender seus clientes? Neste episódio, Tiziano Peres (@tizianoperes), Professor, Treinador e Consultor de Gestão Empresarial, e Caio Reis, Gestor Comercial de Canais e Vendas da MRV, explicaram como explorar a I.A. para transformar negócios e ampliar resultados.

Quer saber como aumentar seu engajamento nas redes sociais, gerar mais vendas e conquistar sua independência financeira na produção de conteúdo utilizando apenas o seu celular? No episódio de hoje, vamos desvendar os segredos da criação de conteúdo de vídeo de alta qualidade e aprender a como dominar essa arte sem precisar de equipamentos caros. Nossos convidados do episódio #135 do Hotmart Cast, são videomakers e especialistas em produção audiovisual há mais de 15 anos. Fill Rocha e Cecília Kraemer já trabalharam com grandes marcas durante a trajetória deles e agora, ensinam iniciantes a criarem conteúdos de qualidade, de forma consistente e gerar resultados expressivos. Aprenda nesse episódio sobre:Investir em em equipamentos caros é um fator predominante para o sucesso?Como criar um roteiro bem estruturado para manter a atenção do seu público?Como o celular por ser um grande aliado na produção de vídeos de alta qualidade?Como criar posicionamento nas redes sociais?Como utilizar Call to Action no encerramento dos seus vídeos?Como explorar diferentes posicionamentos e linguagens para um mesmo produto? ⚡Fill Rocha e Cecília Kraemer são videomakers e especialistas em produção audiovisual há mais de 15 anos e já trabalharam com grandes marcas no Brasil e no mundo, como MRV, Quinto Andar, Meta, Motorola e muitas outras. 00:00 Vídeos podem gerar até 30% mais resultados nas redes sociais04:09 É possível criar vídeos incríveis sem equipamentos caros?10:20 Como criar um roteiro bem estruturado antes de gravar um conteúdo?14:41 Como criar posicionamento nas redes sociais?18:11 Como utilizar ganchos nos seus vídeos para capturar a atenção do público?22:26 Como ser constante nas redes sociais?25:01 Os desafios de produzir conteúdo30:26 O poder do TikTok33:29 As mudanças constantes das redes sociais

Atenção (disclaimer): Os dados aqui apresentados representam minha opinião pessoal. Não são de forma alguma indicações de compra ou venda de ativos no mercado financeiro. Israel e Hamas chegam a acordo de cessar-fogo em Gaza; trégua começará domingo https://www.noticiasagricolas.com.br/noticias/politica-economia/392383-israel-e-hamas-chegam-a-acordo-de-cessar-fogo-em-gaza-tregua-comecara-domingo.html 'Prévia do PIB', IBC-Br sobe 0,1% em novembro, melhor que o previsto https://valor.globo.com/brasil/noticia/2025/01/16/previa-do-pib-ibc-br-sobe-01percent-em-novembro-melhor-que-o-previsto.ghtml BREAKING. Cosan zera posição na Vale e reduz dívida em até 40% https://braziljournal.com/breaking-cosan-zera-posicao-na-vale-e-reduz-divida-em-ate-40/ O que você achou do investimento da Cosan (CSAN3) na Vale (VALE3)? - Live 184 (10/10/22) - Visão https://www.youtube.com/watch?v=hHKhaU8JNtg Cyrela (CYRE3) fecha parceria com fundo canadense CPP Investments com potencial de R$ 6 bilhões – Mo https://www.moneytimes.com.br/cyrela-cyre3-fecha-parceria-com-fundo-canadense-cpp-investments-com-potencial-de-r-6-bilhoes-jcav/ Todas as subsidiárias de MRV geraram caixa pela primeira vez — inclusive a Resia https://exame.com/mercado-imobiliario/todas-as-subsidiarias-de-mrv-geraram-caixa-pela-primeira-vez-inclusive-a-resia/ Melnick (MELK3) anuncia redução de capital mediante restituição em dinheiro aos acionistas - Finance https://financenews.com.br/2025/01/melnick-melk3-anuncia-reducao-de-capital-mediante-restituicao-em-dinheiro-aos-acionistas/ Cade avalia ser 'quase impossível' aprovar fusão entre Gol e Azul sem restrições https://valor.globo.com/empresas/noticia/2025/01/16/cade-avalia-ser-quase-impossivel-aprovar-fusao-entre-gol-e-azul-sem-restricoes.ghtml Cogna (COGN3) aprova programa de recompra de até 7,9% de ações da companhia https://www.infomoney.com.br/mercados/cogna-cogn3-aprova-programa-de-recompra-de-ate-79-de-acoes-da-companhia/ Swamp Notes: Greenland, USA https://podcasts.apple.com/br/podcast/swamp-notes-greenland-usa/id1438449989?i=1000683553322 Why Tech Is Bending the Knee https://podcasts.apple.com/br/podcast/why-tech-is-bending-the-knee/id1302281912?i=1000683644253 Mark Zuckerberg's Meta-Morphosis https://podcasts.apple.com/br/podcast/mark-zuckerbergs-meta-morphosis/id1302281912?i=1000684353999 A Fragile Cease-Fire in Gaza https://podcasts.apple.com/br/podcast/a-fragile-cease-fire-in-gaza/id1200361736?i=1000684218682 The Nazi Ties to Credit Suisse https://podcasts.apple.com/br/podcast/the-nazi-ties-to-credit-suisse/id1469394914?i=1000684145297

Convidado desta edição, Felipe Guerra, sócio e gestor da Legacy Capital, revela por que está pessimista com a economia e os mercados brasileiros neste ano e o que poderia mudar essa visão. Entre os Touros e Ursos da semana, a polêmica do PIX e os números da MRV e da Weg. Confira também o especial Onde Investir em 2025 e saiba onde estão as melhores oportunidades em criptomoedas, ações, renda fixa, ativos internacionais e ações para dividendos: https://www.youtube.com/watch?v=AHB6cd2FBno&list=PLMk0JeT7sIg-kg7HlgOLlasUNAbG9glVb

This new episode features two OAE researchers and their insights from conducting field research as well as a special request to you, our listeners! In this edition of Plan Sea, hosts Anna Madlener and Wil Burns are joined by two leading ocean alkalinity enhancement (OAE) researchers: Dr. Jaimie Palter from the University of Rhode Island's School of Oceanography and Dr. Dariia Atamanchuk from Dalhousie University's Department of Oceanography. Palter and Atamanchuk both lead field research sites studying OAE and are part of Carbon to Sea's Field Research Steering Committee. Palter and Atamanchuk discuss their work leading field research sites studying OAE in coastal lagoon and ocean harbor settings, respectively, and share initial findings. The Plan Sea hosts and this episode's guests underscore the importance of field research guiding the recommendation for scientifically robust, yet affordable and actionable monitoring, reporting, and verification (MRV) processes, and encourage greater collaboration between projects and across the sector.Also: we would like to hear from you, our listeners, before our next episode! Let us know what 2024 milestone we should be celebrating or what you hope to see in 2025 by leaving us a voice message here that may be used in our next episode!Acronyms used throughout the episode: NOAA NOPP –  National Oceanic and Atmospheric Administration's National Oceanographic Partnership Program (1:47) AGU - American Geophysical Union (2:00)MRV - Monitoring, Reporting, and Verification (13:25)pCO2 - Partial pressure of carbon dioxide (34:58)EPA - Environmental Protection Agency (56:27)Plan Sea is a semi-weekly podcast exploring ocean-based climate solutions, brought to you by the Carbon to Sea Initiative & the American University Institute for Responsible Carbon Removal.

Hannah Bebbington is the Head of Deployment at Frontier, an advanced market commitment created in 2022, that aims to purchase $1 billion or more of permanent carbon removal by 2030. Founded by Stripe, Alphabet, Shopify, Meta, and McKinsey, Frontier has quickly become a leading force in the carbon removal space. Its portfolio includes a "who's who" of innovators pushing the boundaries of what's possible in carbon removal—many of whom have been guests on this show. Cody catches up with Hannah to explore how Frontier's program is structured, what they've learned so far, and her perspective on the state of carbon removal today.In this episode, we cover: [2:03] What is Frontier? An intro to its $1B commitment to carbon removal[7:00] The scale of the carbon removal challenge and future funding needs[10:42] Gaps in the industry: demand, investment, and measurement[13:21] Hannah's background and role as Head of Deployment[16:10] Frontier's advanced market commitment model explained[18:05] How Frontier supports early-stage companies through pre-purchases[21:32] Tips for startups applying to Frontier's programs[27:19] Frontier's offtake track for scaling larger projects[30:16] The importance of measurement, reporting, and verification (MRV)[35:05] Frontier's criteria for funding: scale, cost, and permanence[42:14] Microsoft's role as a leader in carbon removal[47:24] Key terms in Frontier's offtake agreements[55:08] The impact of the data center boom on carbon removal[57:01] Carbon removal's bipartisan support and policy outlookRecommended Listening:MCJ Startup Series: Charm IndustrialPermanent Geologic Carbon Storage with Vaulted DeepEnhanced Rock Weathering with Lithos CarbonCarbon Removal and Climate Policy with Heirloom and Senator Scott WienerEpisode recorded on Nov 22, 2024 (Published on Dec 9, 2024) Stay Connected with MCJ:Cody Simms on LinkedIn | XVisit mcj.vcSubscribe to the MCJ NewsletterEnjoyed this episode? Please leave us a review! Share feedback or suggest future topics and guests at info@mcj.vc.

Atenção (disclaimer): Os dados aqui apresentados representam minha opinião pessoal. Não são de forma alguma indicações de compra ou venda de ativos no mercado financeiro. PIB do Brasil desacelera, mas cresce 0,9% no 3º trimestre de 2024 https://exame.com/economia/pib-terceiro-trimestre-2024-ibge/ Pix supera dinheiro e cartão de débito como pagamento mais usado, mostra pesquisa do BC https://br.investing.com/news/economy-news/pix-supera-dinheiro-e-cartao-de-debito-como-pagamento-mais-usado-mostra-pesquisa-do-bc-1410414 Estados aprovam aumento de imposto para compras em sites como Shein e AliExpress; veja nova alíquota https://exame.com/brasil/estados-aprovam-aumento-de-imposto-para-compras-em-sites-como-shein-e-aliexpress-veja-nova-aliquota/ Acordo Mercosul-UE traz 19 capítulos para nortear relação entre os blocos https://istoedinheiro.com.br/acordo-mercosul-ue-traz-19-capitulos-para-nortear-relacao-entre-os-blocos-3/ Casas Bahia tem alta de 20% em vendas nas principais categorias durante Black Friday https://www.cnnbrasil.com.br/economia/mercado/casas-bahia-tem-alta-de-20-em-vendas-nas-principais-categorias-durante-black-friday/ Log antecipa dividendos e anuncia política para 2025; dividend yield bate 8,5% https://braziljournal.com/log-antecipa-dividendos-e-anuncia-politica-para-2025-dividend-yield-bate-85/ MRV muda a rota na Resia: reduz projetos, vende ativos e troca CEO https://braziljournal.com/mrv-muda-a-rota-na-resia-reduz-projetos-vende-ativos-e-troca-ceo/ Pacote de gastos: 'Não há ilusão que medida resolverá todos os problemas do país' https://podcasts.apple.com/br/podcast/pacote-de-gastos-n%C3%A3o-h%C3%A1-ilus%C3%A3o-que-medida-resolver%C3%A1/id1371669233?i=1000679077092 Two Billionaires' Big Plan to Shrink Government https://podcasts.apple.com/br/podcast/two-billionaires-big-plan-to-shrink-government/id1200361736?i=1000679194321 How Drones Are Bringing Emergency Services to Remote Places https://podcasts.apple.com/br/podcast/how-drones-are-bringing-emergency-services-to-remote/id1234320525?i=1000679462662

Confira nossas condições especiais da nossa Black Friday aqui: https://lvnt.app/ud2tyt 18/11 - Bolsa estável, Dólar R$ 5,75, BRAV3 +8% e HAVP3 -6% Olá, seja bem-vindo a mais um Fechamento de Mercado, comigo Flávio Conde e sem o Ricardo que emendou os feriados, hoje é 2ª. feira, 18de novembro, e o programa é dedicado Iane, Matos, Robson, Getúlio, Adriano, Lucileide, Liane, Levy e Rafael que escreveram falando bem do Mata-Mata de Gerdau. Vc que já assistiu compartilhe o link nos seus grupos de whatsapp e quem não assistiu ainda vá agora. Obrigado O Ibovespa fechou estável aos 127.890 pontos com volume razoável de R$ 20 bi, na média de R$ 20 bi das segundas. Por que a Bolsa performou assim? 1º. A bolsa já abriu em baixa indo a 127,4 mil, às 11h15, deu uma estilingada até 128,2 mil, às 11h40, para depois afundar 127,3 mil, às 12h25, para recuperar-se ao longo do dia e fechar perto da estabilidade. Os mercados brasileiros estavam mornos hoje em função de parte de investidores terem emendado os dois feriados e a falta de notícias macro e micro que fizessem os preços dos ativos ficarem de lado com o dólar recuando quatro centavos, os juros subindo um pouco e as ações de lado. Na B3, as ações de petrolíferas subiram seguindo a alta do preço do petróleo, mineradoras e siderúrgicas avançaram com a subida do minério na China e algumas varejistas como Magalu, Cogna, Hypera, Assaí e RaiaDrogasil. Nas quedas, Hapvida, Azul, BRF, MRV, Cemig e Ultrapar. 2º. Na B3, 5 ações subiram entre as 15 ações mais negociadas com destaques para: PETR4 2,2% R$ 38,11 com investidores animados com o novo plano estratégico que pode garantir dividendos altos, VALE3 1,4% R$ 57,66 seguindo a alta do minério, BBAS3 1% R$ 25,64, BBDC4 1,7% R$ 13,76 e PETR3 2% R$ 41,36. 3º. Já 10 ações caíram entre as mais negociadas com destaques para: B3SA3 -2,2% R$ 10,04, ITUB4 -0,20% R$ 34,34, JBSS3 -0,6% R$ 34,98 e ABEV3 -1,7% R$ 12,42. 4º. O preço do petróleo teve alta forte de 3%, a US$ 73,3 de US$ 71,3, na sexta, acima do limite da volatilidade diária de -/+2%, após notícias de que a produção de petróleo bruto no campo petrolífero norueguês Johan Sverdrup havia sido interrompida, o que se somou a alta decorrentes da potencial escalada da guerra Rússia-Ucrânia depois que o presidente Biden autorizou os ucranianos a usar mísseis americanos de longo alcance, até 300 km. 5º. O minério de ferro subiu 1,90% a US$ 105,1 de US$ 103, na sexta, num movimento de compra por parte de traders depois de dias de quedas. 6º. As bolsas americanas tiveram comportamento mistos hoje, 0,60% Nasdaq e -0,13% Dow, junto com o dólar que desvalorizou -0,40% frente moedas fortes e os juros dos títulos de 10-anos que recuaram de 4,44% para 4,42% a.a. com investidores na defensiva depois do presidente do Fed, Jerome Powell, alertar na sexta-feira que era provável que os juros fossem reduzidos numa velocidade menor do que o esperado frente as incertezas do próximo governo. 7º. O dólar à vista recuou quatro centavos de R$ 5,79 para R$ 5,75, -0,70%, o dobro da volatilidade média de -2/+2 centavos por dia, com investidores realizando lucros das altas da moeda norte-americana na semana passada. 8º. O saldo de investimentos estrangeiros no mercado secundário da Bovespa, de ações já em circulação, ficou positivo em R$ 95,7 milhões na quarta-feira, 13 de novembro, segundo dados da B3. Com esse resultado, o saldo negativo dos estrangeiros no mercado secundário acumulado no mês caiu para R$ 438,9 milhões. No acumulado do ano, os estrangeiros tiraram da Bovespa R$ 23,290 bilhões, com vendas líquidas de R$ 31,200 bilhões no mercado secundário e compras de R$ 7,910 bilhões em ofertas públicas. Os estrangeiros respondem por 57,50% do volume negociado na Bovespa neste mês e por 55,50% do acumulado no ano.

Tao Climate, a leading innovator in carbon removal measurement, reporting and verification (MRV) technology, is proud to announce that it has joined the prestigious European Space Agency (ESA) Business Incubation Centre (BIC) Ireland programme. This collaboration marks a significant milestone in Tao Climate's mission to harness space technology to drive sustainability in industrial hemp cultivation. Through this programme, Tao Climate will integrate advanced satellite imaging technology developed by ESA into its MRV platform to monitor the growth of industrial hemp, a versatile crop known for its significant carbon absorption capabilities. This initiative will enable precise tracking of hemp cultivation by Tao Climate's partners, providing critical data to ensure optimal growth conditions and maximise the crop's carbon removal potential. Tao Climate is poised to address one of the most pressing challenges in the carbon removal market: verification. By leveraging ESA's satellite technology, Tao Climate aims to develop a robust system for accurately verifying carbon removal from hemp cultivation. This innovation will not only enhance transparency in the carbon market but also incentivise sustainable farming practices on a global scale. Gary Byrnes, CEO of Tao Climate, expressed his enthusiasm for the collaboration: "The intersection of space technology and sustainability is where we see the future. By leveraging the European Space Agency's satellite imaging capabilities, we can monitor hemp growth with unprecedented accuracy, solve the carbon credit verification problem, and build a foundation for a more sustainable future. This partnership is a testament to the transformative power of space tech in tackling the climate crisis." Peter Finnegan, ESA Space Solutions Ireland Manager, said: "We are delighted to welcome Tao Climate to the ESA Business Incubation Centre (BIC) Ireland network. Their innovative use of space technology to address global challenges, such as carbon removal through industrial hemp cultivation, illustrates the types of pioneering technology that we aim to support. "By integrating ESA's satellite imaging technology into their platform, Tao Climate is not only advancing the verification of carbon removal but also demonstrating the transformative impact space assets can have on sustainability efforts." ESA BIC Ireland supports Irish companies across the business spectrum that are developing technologies using space assets, resources or solutions that can be used in space. The initiative is managed by ESA Space Solutions Ireland, a Consortium Partnership made up of the following entities: Tyndall National Institute (Lead Partner), Dublin City University, Maynooth University, Technological University of the Shannon, and University College Dublin. The ESA BIC Ireland programme provides Tao Climate access to technical expertise, funding opportunities, and a network of space industry leaders, positioning the company at the forefront of the global technology movement towards a greener, more sustainable planet. See more stories here.

Get the latest insights from the AAMBITION Podcast delivered straight to your inbox. Subscribe HERE.++++Episode 31 of the “Aerospace Ambition Podcast” featuring Andrew Chen (RMI) is out!Talking Points• What does your research reveal that was previously unknown?• Why has the Contrail Impact Taskforce gone for a 100-pages PDF report and who was this intended to reach?• Should researchers take a more active role in communicating the importance of the problem on platforms beyond research papers?• If the measurement of the climate impact, as opposed to modelling of this effect, is still a todo, how do we know that we need to act already?• How do you respond to stakeholders claiming that even four trials the certainty is not enough?• What does the statement about the inescapability of GWP100 in climate impact accounting mean, and shouldn't we advocate for more ambitious metrics given its limitations and the urgency of climate goals?• Why does the report not make a clear recommendation regarding the scope of the aviation MRV for non-CO2 effects?• Given that CORSIA currently focuses on CO2, have we reached a point where the science and forecasting of contrails and their radiative forcing is advanced enough to consider a future version of CORSIA that includes non-CO2 effects like contrails?GuestAndrew Chen is the principal for aviation decarbonization at RMI, where he leads the aviation team's efforts to accelerate the transition to net-zero air transport. With over 15 years of experience in sustainability strategy, environmental impact assessment, and emissions management, Andrew is a passionate and experienced leader in the field of decarbonization.

Preencha o formulário e conheça o programa mais completo de consultoria e aconselhamento da Levante https://lvnt.app/jtnp7n O Ibovespa sobe pelo sexto dia consecutivo, 0,94%, aos 132.349 mil pontos e bom volume de R$ 24 bi, R$ 1 bi abaixo das médias de R$ 25 bi das terças, com investidores americanos comemorando a inflação ao produtor de julho em apenas 0,10% versus 0,20% esperado e só 2,2% em doze meses. Por que a Bolsa performou assim? 1º. A bolsa já abriu em alta e a inflação ao produtor de julho em apenas 0,10% versus 0,20% esperado e só 2,2% em doze meses. Assim, ações dos EUA, Brasil e mundo subiram mais e juros e dólar caíram. Aqui na B3, quase tudo subiu menos Petrobras e Vale porque petróleo e minério recuaram. Já bancos dispararam porque dólar e juros futuros menores é favorável aos resultados dos bancos. As ações de varejo avançaram por conta dos juros menores bem como carnes. Só caiu mesmo Natura por conta de resultados abaixo do esperado, Yduqs, Petz, Cogna, MRV, Alpargatas, EZtec e Cyrela. 2º. Entre as 15 ações mais negociadas 12 subiram lideradas em volume negociado por: ITUB4 2,50%, B3SA3 3,30%, WEGE3 0,90%, SBSP3 1,10%, MGLU3 2,50%, BBDC4 1,10%, PRIO3 0,90%, BBAS3 1,20%, LREN3 0,20%, SUZB3 0,10% e RAIL3 0,10%. 3º. Três ações caíram entre as 15 mais negociadas: PETR4 R$ -0,40%, VALE3 -0,35% e RENT3 -1,60 %. Faz tempo que alerto sobre a situação menos favorável de Localiza e as ações caem -22% no ano. 4º. O preço do petróleo caiu 1,80% para US$ 80,7 de US$ 82, ontem, dentro da volatilidade diária de -/+2%, depois que Agência Internacional de Energia reduziu ligeiramente o aumento da demanda por petróleo de 980 mil para 950 mil barris por dia. 5º. O preço do minério de ferro caiu -1,0% para US$ 101,6 de US$ 102,7 por tonelada, sext6a, e ainda abaixo dos US$ 110 e se aproximando dos US$ 100. Portanto, continua a preocupação com o preço do minério de ferro devendo fazer os resultados do 3T24 serem menores que o 2T24. Em função disso, as ações da VALE vão caindo lentamente todo dia. 6º. As bolsas americanas em forte alta com Nasdaq 2,40% e Dow Jones 1,00%. Investidores voltaram ao mercado e comprando bem depois da inflação ao produtor ter vindo em apenas 0,10% versus 0,20% esperados. A quantidade de investidores esperando um corte de -0,50% nos fed funds em setembro aumentou, mas continuo com -0,25%. De toda forma, é muito bom para bolsas americanas, brasileiras e de todo mundo. 7º. O dólar à vista recuou mais ainda para R$ 5,45, quatro centavos abaixo dos R$ 5,49 de ontem, influenciado pela inflação menor ao produtor que derrubou os juros longos para 3,85% de 3,90% ontem enfraquecendo o dólar no mundo. 8º. Nos EUA, os juros dos títulos de 10-anos caíram mais indo de 3,90 % a.a. para 3,85 % a.a. com a inflação ao produtor mais baixa em julho. No Brasil, as taxas de juros dos títulos do Tesouro do Brasil recuaram junto das americanas com o Prefixado 2031 indo de 11,68% a.a. para 11,55% a.a. Entretanto, esses juros longos no Brasil ainda é muito alto, pois em dezembro de 2023, faz 8-9 meses era de 9,60% a.a. De toda forma, as quedas dos juros longos tem ajudado as ações brasileiras a subir e se aproximar dos 134,1 mil do fechamento de dezembro 2023. 9º. Os investidores estrangeiros compraram líquido R$ 687 milhões em recursos no segmento secundário da B3 Cotação de B3 (ações já listadas) na sexta-feira, dia 9, quando Ibovespa subiu 1,52%. No mês de agosto o saldo está positivo em R$ 1,7 bilhão. Já no ano, o saldo negativo do ano está R$ 30,4 bilhões e o Ibovespa recua -2,9%. Percebam a importância dos investimentos dos estrangeiros no segmento secundário de ações da B3: em agosto, os estrangeiros respondem por 57,10% do volume negociado na Bovespa e 54,90% do acumulado no ano. MAIORES ALTAS CMIN3 +6.29% R$ 5,24 IRBR3 +5.88% R$ 31,89 CSNA3 +4.37% R$ 12,19 JBSS3 +4.21% R$ 34,90 AZUL4 +4.00% R$ 7,28

Episode 28 of the “Aerospace Ambition Podcast” featuring Eóghain Mitchison (easyJet) is out!Talking Points• What is the MRV, and why is it important to make aviation more sustainable?• What should be the scope of the MRV for non-CO2 effects, and why?• How do you perceive lobbying activities around contrail management?• How much of a fuel penalty would easyJet be willing to pay? • Does easyJet measure, report and verify already?• Who would suffer the most from a reduction in scope?GuestEóghain Mitchison is a Senior Policy Manager at easyJet. He represents easyJet in discussions with the EU and national governments on technical aspects of government policy, with a focus on climate regulations. His recent work has been centered on the 'Fit for 55' package of climate legislations, including the EU SAFs mandate (ReFuelEU) and the revision of the EU ETS.AAMBITION Newsletterhttps://mailchi.mp/55033eb444bd/aambition-n

Este conteúdo é um trecho do nosso episódio: “#260 - Chatbots inteligentes foram a aposta certeira da MRV”. Nele, Natasha Resende, Tech Leader da MRV, compartilha alguns detalhes e desafios do case da empresa que revolucionou sua área comercial e de atendimento ao público. A transformação foi marcada pela eficiência e humanização proporcionadas pelo uso de chatbots. Ficou curioso? Então, dê o play! Quer conversar com Os Agilistas? É só mandar sua dúvida/sugestão na nossa página do Linkedin ou pelo e-mail osagilistas@dtidigital.com.br que nós responderemos em um de nossos conteúdos! Nos acompanhe pelas redes sociais e assine a nossa newsletter que chega todo mês com os assuntos quentes do agilismo através do site.See omnystudio.com/listener for privacy information.

As Running Tide folds and Microsoft and Google scramble to figure out how to make up for rising emissions from AI and data centres, what's next for the carbon removals market?Recovering lawyer John Lin and Dr. Amber Janda, co-founders of Tau Carbon, join us to discuss. They discuss their journey from academics and different career paths to establishing a company focused on carbon removal using innovative biomass storage solutions. The conversation explores the inspiration behind their venture, the technical and logistical challenges they faced, and the implications of carbon market dynamics. Highlighting the importance of low-cost, scalable solutions, Tau Carbon aims to preserve biomass in an above-ground system to efficiently capture and retain CO2. The co-founders also reflect on the competitive landscape, referencing similar startups like Graphyte, and discuss policy needs to support broader adoption of carbon removal technologies.Wicked Problems is member-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.00:00 Introduction to Wicked Problems00:14 Inspiration and Challenges in Climate Tech01:24 UK Climate Politics and Global Tech Reactions03:18 Introduction to Tau Carbon04:34 John's Journey from Law to Climate Tech06:48 Amber's Path in Chemical Engineering09:58 The Genesis of Tau Carbon14:37 Challenges and Evolution in Carbon Removal20:00 Business Viability and Market Challenges25:11 Reacting to Running Tide's Unexpected Exit25:57 Challenges in Carbon Credit Market27:23 Measurability and MRV in Carbon Removal28:04 Technical Aspects of Carbon Storage31:39 Comparing Approaches: Tau vs. Graphyte37:08 Policy and Market Dynamics in CDR42:35 Future Prospects and Final ThoughtsCatalysts for John and Amber* Greta Thunberg - John was deeply inspired by Greta Thunberg's activism, which galvanized people worldwide to take action on climate change. Her ability to mobilize masses highlighted the power of collective action.More about Greta Thunberg* "An Inconvenient Truth" by Al Gore - Both John and Amber cited this seminal documentary as a major influence. It played a pivotal role in raising awareness about the urgency of climate change and inspired them to pursue solutions in this field.Watch "An Inconvenient Truth" on Amazon* "Good Night, and Good Luck" (2005) - Amber mentioned this film about Edward R. Murrow's battle against Senator McCarthy as influential. It underscored the importance of using one's skills and platforms for the greater good.Watch "Good Night, and Good Luck" on AmazonSubscribe at wickedproblems.earth to get ad-free episodes and support our work. Hosted on Acast. See acast.com/privacy for more information.

【YouTubeで日本語字幕付き公開中】https://youtu.be/NNnGucpl5nE ナン・ランソホフ氏は、FrontierとStripe ClimateのHead of Climateを務め、炭素除去市場の立ち上げに注力している。https://frontierclimate.com/ https://stripe.com/climate  ＜目次＞(00:00) Stripe の気候イニシアチブ(00:54) Nan Ransohoffさんについて(02:14) Stripe Climate と Frontier: 炭素除去の市場の構築(03:26) Stripe Climate の起源と進化(06:04) 高度な市場コミットメントとその影響(07:23) 炭素除去マーケットプレイスを立ち上げる理由(08:34) 革新的な炭素除去技術(14:03) 炭素除去スタートアップのサポートと拡大(23:14) MRV（測定、報告、検証） の重要性(27:02) 高度な市場コミットメント(32:03) ソリューション セットの多様性と価格設定の問題(34:52) ポジティブな持続可能性(37:15) 持続可能性について学ぶ場所(38:57) Nan の炭素除去への道(40:39) 過去 4 年間の学び(43:00) Stripe の気候チームの所在地 Interview: Tetsuro MiyatakeFilm, Edit & Translate: Miki Kusano ＜About Off Topic＞Podcast:Apple - https://apple.co/2UZCQwzSpotify - https://spoti.fi/2JakzKm Off Topic Clubhttps://note.com/offtopic/membership X - https://twitter.com/OffTopicJP 草野ミキ:https://twitter.com/mikikusanohttps://www.instagram.com/mikikusano 宮武テツロー: https://twitter.com/tmiyatake1

Este conteúdo é um trecho do nosso episódio: “#260 - Chatbots inteligentes foram a aposta certeira da MRV”. Nele, Natasha Resende, Tech Leader da MRV, fala sobre como a avaliação constante dos clientes em relação aos seus chatbots foi crucial para eles expandirem para outras soluções personalizadas desse modelo. Nossos hosts também comentam sobre a importância de saber diferenciar a necessidade de adotar uma inteligência artificial ou uma árvore de decisões para uma solução. Ficou curioso? Então, dê o play! Quer conversar com Os Agilistas? É só mandar sua dúvida/sugestão na nossa página do Linkedin ou pelo e-mail osagilistas@dtidigital.com.br que nós responderemos em um de nossos conteúdos! Nos acompanhe pelas redes sociais e assine a nossa newsletter que chega todo mês com os assuntos quentes do agilismo através do site.See omnystudio.com/listener for privacy information.

E se os chatbots fossem responsáveis por 47% das vendas do seu negócio? Isso é realidade na MRV. Para falar sobre o case incrível da Super Mia, recebemos Natasha Resende, Tech Leader da MRV e Emmanuelle Quites, Tech Manager da dti digital. Ficou curioso? Então, dê o play! Quer conversar com Os Agilistas? É só mandar sua dúvida/sugestão na nossa página do Linkedin ou pelo e-mail osagilistas@dtidigital.com.br que nós responderemos em um de nossos conteúdos! Nos acompanhe pelas redes sociais e assine a nossa newsletter que chega todo mês com os assuntos quentes do agilismo através do site.See omnystudio.com/listener for privacy information.

Episode 27 of the “Aerospace Ambition Podcast” featuring Prof. Manuel Soler (Carlos III University of Madrid) is out!Talking Points• What are the goal and scope of E-CONTRAILS?• How can we address the delays in data availability from the Meteosat Third Generation satellite, and how will E-CONTRAILS handle this issue?• How can neural networks assist in assessing water vapor measurements? (Question from Dr Carmen Emmel)• Was the attention given to the topic of ground-based observation at the Pycontrails event justified?• Is the research community overly dependent on CoCiP?• Should the MRV place greater reliance on observational data?GuestManuel Soler is a Professor in the Department of Aerospace Engineering at UC3M in Madrid. He serves as the Director of the Doctoral Program in Aerospace Engineering, leads the UC3M Aeronautical Operations Laboratory, and co-founded the Spin-Off AI-Methods. His research focuses on mitigating the climate impact of aviation, particularly contrails. Manuel Soler has participated in numerous European projects related to contrails (e.g., FLYATM4E and ALARM, where he helped develop the ClimaCCF library). He is currently the coordinator of the E-CONTRAIL project, which aims to develop artificial neural networks (utilizing remote sensing detection methods) to predict the climate impact of contrails and aviation-induced cloudiness. This work contributes to a better understanding of the non-CO2 impact of aviation on global warming and helps reduce associated uncertainties, essential steps towards green aviation.Linkedin Profiles• Manuel: https://www.linkedin.com/in/manuel-soler-32716335/• Marius: https://www.linkedin.com/in/mariuswedemeyer/Resources• Abolfazl Simorgh, Manuel Soler. Pathways to Sustainable Aviation: Aligning Flight Plans with Climate Goals, 03 June 2024, PREPRINT (Version 1) available at Research Square https://doi.org/10.21203/rs.3.rs-4355046/v1AAMBITION Newsletterhttps://mailchi.mp/55033eb444bd/aambition-n

O Ibovespa, principal índice acionário do país, abriu a semana em alta de 1,07%, aos 122,6 mil pontos.O indicador foi puxado pela melhora nas perspectivas para os juros futuros, após decisão unânime do Banco Central pela manutenção da Selic em 10,50% ao ano.O destaque do dia, no mercado de renda variável, ficou por conta do anúncio da parceria dos market places da Magalu com a chinesa Aliexpress.A ação da brasileira encerrou o dia em alta de 12,28%, a maior entre as componentes do Ibovespa. Hapvida (+5,99%) e MRV (+5,43%) seguiram a varejista para completar as três principais altas da segunda-feira,24.Ser Antagonista é fiscalizar o poder. Apoie o jornalismo Vigilante:  https://bit.ly/planosdeassinatura   Acompanhe O Antagonista no canal do WhatsApp.  Boletins diários, conteúdos exclusivos em vídeo e muito mais.   https://whatsapp.com/channel/0029Va2S...   Ouça O Antagonista | Crusoé quando quiser nos principais aplicativos de podcast.  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

Vagas liberadas! Luisa Pires revela a lista das criptos com o maior potencial de valorização: https://lp.levanteideias.com.br/roc03v/ 20/06 - MERCADO gostou do COPOM, Bolsa 0,15%, mas DÓLAR R$ 5,46 A Bolsa registrou leve alta de 0,15%, aos 120.4461 pontos e volume razoável de R$ 21 bi, R$ 4 bi abaixo dos R$ 25 bi das quintas de dezembro. Por que a Bolsa performou assim? 1º. A bolsa abriu em alta com investidores comemorando a unanimidade do COPOM, nova fala de Lula hoje fez bolsa recuar e fechar apenas com leve alta. Vale, Petrobras, BB e WEG subiram enquanto MRV, Azul, Magalu e Embraer caíram. 2º. Entre as 15 ações mais negociadas 8 subiram lideradas em volume negociado por: PETR4 1,6%, VALE3 0,90%, BBAS3 0,50%, WEGE3 2,4% e RAIL3 0,30% 3º. Sete ações caíram entre as 15 mais negociadas sendo as principais: ITUB4 -0,70%, BBDC4 -0,30%, B3SA3 -1,3%, SBSP3 -0,10% e MGLU3 -3,3%. 4º. O petróleo subiu 0,70%, para US$ 85,7 de US$ 85,1, ontem, dentro da volatilidade diária de -/+2%, e sem novidades 5º. O minério de ferro quase estável, 0,10% para US$ 113,5 de US$ 113,4 ontem, e sem novidades. 6º. As bolsas americanas voltaram do feriado com performance opostos, pois o Nasdaq recuou -0,78% e o Dow Jones 0,77%. O Nasdaq caiu porque a estrela da vez, a Nvidia, caiu -3,7% contaminando parte do mercado. Já o Dow Jones avançou com Chevron, Johnson & Johnson, Merck e McDonald´s. 7º. O dólar subiu mais 2 centavos, para R$ 5,46 de R$ 5,43, ontem, depois de abrir em queda por causa do COPOM e subir a tarde com a fala de Lula criticando, de novo, o Banco Central. 8º. Os juros dos 10-anos dos títulos do Tesouro dos EUA voltaram a subir e foram de 4,22%¨para 4,26% a.a. Os juros dos títulos do Tesouro do Brasil caíram com os juros do Prefixado 2031 (cerca de 7 anos), indo de 12,32% para 12,24% a.a. 9º. O saldo de investimentos estrangeiros no mercado secundário da Bovespa, de ações já em circulação, ficou negativo em R$ 570 milhões na terça-feira, 18 de junho, segundo dados da B3. No mês de junho, o saldo está negativo em R$ 7,4 bilhões em apenas nove dias de pregão. No acumulado do ano, os estrangeiros tiraram da Bovespa R$ 42,0 bilhões. Os estrangeiros respondem por 51,70% do volume negociado em junho e por 54,5% do volume acumulado no ano. Já Pessoas físicas respondem por 12,40% do volume em junho, menor do que os 13,50% do acumulado no ano. Já os investidores institucionais aumentaram participação para 30% do volume do mês versus 27% do acumulado em 2024. MAIORES ALTAS RECV3 +4.85% R$ 18,80 USIM5 +3.68% R$ 7,61 SMTO3 +3.53% R$ 32,88 CCRO3 +2.49% R$ 11,92 WEGE3 +2.44% R$ 40,78 MAIORES BAIXAS MRVE3 -4.23% R$ 6,57 AZUL4 -4.09% R$ 7,73 MGLU3 -3.34% R$ 10,71 EMBR3 -2.31% R$ 36,35 HYPE3 -2.11% R$ 28,79 Conheça a Levante Investimentos: Conheça nossas *Séries de Investimentos*: https://lvnt.app/4q3u3b Acompanhe nosso Instagram:   / levante.investimentos   Fique ligado nas principais notícas do mercado no nosso canal no Telegram: https://lvnt.app/zuntm0

On today's American Warrior Show we will be joined by our co-host Mike Seeklander. Mike and Rich will discuss the specter of nuclear war. We will delve into the history, likelihood, and even specific scenarios. This show is inspired by Annie Jacobsen's amazing new book, Nuclear War: A Scenario. Join us!   Buy a copy of “Nuclear War: A Scenario” by Annie Jacobsen https://a.co/d/cS9F5dM   American Warrior Show: https://americanwarriorshow.com/index.html   SWAG: https://shop.americanwarriorsociety.com/   American Warrior Society please visit: https://americanwarriorsociety.com/

New daily persistent headache is a syndrome characterized by the acute onset of a continuous headache in the absence of any alternative cause. Triggers are commonly reported by patients at headache onset and include an infection or stressful life event. In this episode, Aaron Berkowitz, MD, PhD, FAAN, speaks with Matthew Robbins, MD, FAAN, FAHS, author of the article “New Daily Persistent Headache,” in the Continuum® April 2024 Headache issue. Dr. Berkowitz is a Continuum® Audio interviewer and professor of neurology at the University of California San Francisco, Department of Neurology and a neurohospitalist, general neurologist, and a clinician educator at the San Francisco VA Medical Center and San Francisco General Hospital in San Francisco, California. Dr. Robbins is an associate professor of neurology and director of the Neurology Residency Program at New York-Presbyterian/Weill Cornell Medical Center in New York, New York. Additional Resources Read the article: New Daily Persistent Headache Subscribe to Continuum: continpub.com/Spring2024 Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @https://twitter.com/AaronLBerkowitz Guest: @ @mrobbinsmd Full Transcript Available: Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, a companion podcast to the journal. Continuum Audio features conversations with the guest editors and authors of Continuum, who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article by visiting the link in the Show Notes. Subscribers also have access to exclusive audio content not featured on the podcast. As an ad-free journal entirely supported by subscriptions, if you're not already a subscriber, we encourage you to become one. For more information on subscribing, please visit the link in the Show Notes. AAN members: stay tuned after the episode to hear how you can get CME for listening.   Dr Berkowitz: This is Dr Aaron Berkowitz, and today I'm interviewing Dr Matthew Robbins about his article on new daily persistent headache, from the April 2024 Continuum issue on headache. Dr Robbins is an Associate Professor of Neurology and Director of the Neurology Residency Program at New York-Presbyterian/Weill Cornell Medical Center, in New York. Welcome to the podcast. Dr Robbins: It's great to be with you, Dr Berkowitz. Dr Berkowitz: Well, thanks so much for joining us this morning. To start, what is new daily persistent headache? I think it's an entity maybe that might be new to some of our listeners. Dr Robbins: Yeah - it's an entity that also struck me when I was in training. I didn't hear much of it as a neurology trainee until I did a fellowship in headache, where, all of a sudden, we were seeing patients with this syndrome (and labeled as such) all the time. And that actually inspired me to begin a research project to better characterize it - a clinical project that ended up helping to broaden the diagnostic criteria. New daily persistent headache really is just defined by what it says - it's new; it's every day; it persists; it's a headache. It can't be from some other identifiable cause, which includes both secondary disorders (you know, something that, where headache is a symptom of) or a primary headache disorder; distinguishes itself from, say, migraine or tension-type headache because there's no real headache history and there's an abrupt onset of a daily and continuous headache that has to last for at least three months since onset. And the onset is typically remembered - it's usually acute or abrupt; there may or may not be some circumstances that surrounded the onset that might have some diagnostic or causal or associated implications that we can explore. Dr Berkowitz: Okay. So, I always find it challenging in headache medicine and some other areas where we don't have a biomarker, per se - an imaging finding, a lab finding; we have an eloquent and detailed clinical description - to know how comfortable to be making a diagnosis like this. In this case, particularly, right - you said it has to be going on for three months. What if I see a patient one month into something I think could be this, but I can't technically say, per the criteria, right (it's three months)? When do you start thinking about this diagnosis in patients, and what are some of the main considerations in confirming the diagnosis, and what needs to be ruled out or excluded for making the diagnosis?   Dr Robbins: I think traditionally, in headache, the term “chronic” has that three-month time period. The reasons are twofold: one is that, typically, if there's some secondary disorder that might have some distinguishing feature (something that really evokes the headache or some other neurological accompaniment that develops in addition to headache), it would pretty much be likely to declare itself by the three-month mark. Or if it was something that was very self-limited, it would probably go away before three months have elapsed. Or if it resolved after some days or weeks but then declared itself as a more episodic disorder, then we might say someone who begins with continuous headache that might, for example, resemble migraine (maybe it presented a status migrainosis but then it devolved into a more episodic disorder that might just be migraine overall). So, I think that's pretty much why the three-month mark has been so prevalent in the International Classification of Headache Disorders, including how new daily persistent headache is diagnosed. But at the same time, there's lots of disorders that might mimic (or might be misdiagnosed as) new daily persistent headache, and they really are a secondary disorder. Probably the most common one that we think about is a disorder of intracranial pressure or volume, mainly because routine MRI features could be normal or could be easily missed if they had subtle abnormalities. The defining symptom of those disorders are also continuous headache, often from onset, with an abrupt and remembered nature. So, that's often the main category of secondary headache that might be misdiagnosed as primary headache. I think, probably, idiopathic intracranial hypertension as the prototypical disorder of high pressure often declares itself with visual symptoms, pulsatile tinnitus, and other abnormalities. And nowadays, there's much more increasing recognition for MRI abnormalities or even MRV abnormalities with such patients. But spontaneous intracranial hypotension (despite increasing recognition of CSF leaks in the spine that lead to intracranial hypotension or hypovolemia) really remains an underdiagnosed entity. I think that's one disorder where - for example, if I'm seeing a patient with new daily persistent headache and there's no orthostatic or positional nature to their headache - I will still do an MRI, with and without contrast, to be sure. But that the chances of them having a spontaneous CSF leak are low if that scan is unremarkable. Dr Berkowitz: That's very helpful. Yeah. It's interesting; when you talked about the criteria for this condition - that it has an acute onset, which is a red flag, right, and it is persistent for months, which for a new headache would also be a red flag. So, this is a condition - correct me if I'm wrong – that, if you're considering it, there's no way that you're going to make this diagnosis without neuroimaging because there are two red flags, in a way, embedded in the criteria before we get to the other diagnoses being excluded. Is that right? So, this would only be a diagnosis made clinically but after neuroimaging is obtained, given that two red flags are part of the criteria – isn't that right? Dr Robbins That's absolutely right. So, I can't imagine there's anyone who has new daily persistent headache who hasn't had appropriate neuroimaging, and that typically should include an MRI, with and without contrast, unless there's some compelling reason to avoid that. There's some other workup that could be done that's not universal but - for example, in clinic-based studies of patients who have new daily persistent headache versus those who may have, say, chronic migraine or chronic tension-type headache, you may find more abnormalities. The biggest and more compelling example of that is hypothyroidism, which presumably would be somewhat subclinical if it hadn't been brought to someone's medical attention earlier. It doesn't mean that hypothyroidism is the cause of new daily persistent headache, but it could be some type of triggering or priming factor that leads to headache perpetuation in some patients. Sometimes, if that hasn't been done already, that would be a blood test I might think about sending. And, of course, the context of onset; if someone lived in a place where tick-borne illnesses are endemic, if there are other neurological symptoms, that might prompt looking for serological evidence of Lyme disease, as one example. Dr Berkowitz: We see a lot of headache. I'm a general neurologist; I know you're a headache specialist; we all see a lot of patients with headache. You and I both work closely with residents. Often, residents will come to present a headache patient to me and they'll say, “The patient seems to have a new daily persistent headache. They haven't been imaged yet. They have a completely normal exam. The history fits.” And I always ask them, “Okay, we have to get neuroimaging, right? There's at least one red flag of the chronicity, maybe the red flag of something beginning relatively abruptly. Even though you're looking at the patients - I'm pretty sure that imaging is going to be normal, but we've got to do it.” But I always encourage residents, “Try to predict - do you think the imaging is going to be normal (this is a rule out) or do you think you're going to see something (this is a rule in)? - just to sort of work on calibrating your clinical judgment.” I'd love to ask you - as a headache specialist, when you're looking at the patient and say, “I know I need to get neuroimaging here to fully make this diagnosis of exclusion,” or you've heard something that sounds like a red flag; you know you're obligated to image, but your clinical suspicion of finding anything more than something incidental is pretty low. How often are you surprised in practice in a sort of enriched tertiary headache population? Dr Robbins: That's a great way to frame such a presentation on how a resident would present to you the case and whether it's a rule in or rule out. I totally agree with your approach. I think much of it depends on the clinical story. I think if it was just a spontaneous onset of headache that kind of resembles migraine that just continued, then likely the MRI is being done to just be sure we're not missing anything else. However, if the headache started – really, say someone coughed vigorously or bent over and the headache started, and there was some clear change that you could perceive in - that was, say, the Valsalva or a transiently raised intracranial pressure, or some other maneuver; then you might really say, “Well, this really could be a spontaneous CSF leak,” for example. Even if the MRI of the brain, with and without contrast, is totally normal, I'm not really sure I'm convinced - that you might even take it further. For example, you might do an MRI of the total spine, with a CSF-leak-type protocol, to see if there's some sign of a spontaneous CSF leak or an extradural collection. So, I think in the cases where the preclinical suspicion is higher for a secondary headache, it might not stop at an MRI of the brain (with and without contrast) that's normal. Patients with spontaneous CSF leaks - about eighty percent of them have abnormal brain MRIs, but twenty percent don't. We found, from some observational studies, that a newer cause of intracranial hypotension, such as a CSF venous fistula in the spine, is more likely to present than other causes of CSF leak - with say, Valsalva-associated headache or cough-associated headache. That might prompt us to really take a workup more deeply into that territory, rather than someone where it really just sounds like chronic migraine that switched on. And maybe in those patients, when you dig around, they were carsick as a kid, or they were colicky babies, or they used to get stomachaches and missed school as a teenager here and there, and you think migraine biology is at play. Dr Berkowitz: So, if you're thinking of this diagnosis before you can make it, these patients are going to get an MRI, with and without contrast. And it sounds like the main things you're looking to make sure you're not missing are idiopathic intracranial hypertension or intracranial hypotension from some type of leak. Any other secondary headaches you worry about potentially missing in these patients or want to rule out with any particular testing? Dr Robbins: Yeah - I think sometimes we think of other vascular disorders, especially - when these patients come to medical attention, it's often a total change from what they're used to experiencing. They may present to the emergency room. So, it depends on the circumstance. You might need to rule out cerebral venous thrombosis. Or if there was a very abrupt onset or a relapsing nature of abrupt-onset headaches with sort of interictal persistent headache, we might think of other arteriopathies, such as reversible cerebral vasoconstriction syndrome. There's the more common things to rule out - or commonly identified conditions to rule out - like neoplasm and maybe a Chiari malformation in certain circumstances; those usually would declare themselves pretty easily and obviously on scan or even on clinical exam. Dr Berkowitz: Another question I'd love to ask you as a headache specialist, in your population - sometimes we see this type of new daily persistent headache presentation in older patients, and the teaching is always to rule out giant cell arteritis with an ESR and CRP, in the sense that older patients can present with just headache. Again, my clinical experience as a general neurologist - I wanted to ask you as a headache specialist – is, for the countless times I've done this (older patient has gotten their neuroimaging; we've gotten ESR and CRP), I've never made a diagnosis of giant cell arteritis based on a headache alone, without jaw claudication, scalp tenderness, visual symptoms or signs. Have you picked this up just based on a new headache, older person, ESR, CRP? I'm going to keep doing it either way, but just curious - your experience. Dr. Robbins: Yeah. We're taught in the textbooks (I'm sure we're taught by past Continuum issues and maybe even in this very issue) about that dictum that's classically in neurology teaching. But I agree - I've never really seen pure daily headache from onset, without any other accompaniments, to end up being giant cell arteritis. Then again, someone like that might walk in tomorrow, and the epidemiology of giant cell arteritis supports doing that in people over the age of fifty. But almost always, it's not the answer; I totally agree with you. Dr Berkowitz: Good to compare notes on that one. Okay - so let's say you're considering this diagnosis. You've gotten your neuroimaging, you've gotten (if the patient is over fifty) your ESR and CRP, and you ruled out any dangerous secondary causes here. You have a nice discussion in your article about the primary headache differential diagnosis here. So, now we're sort of really getting into pure clinical reasoning, right, where we're looking at descriptions (colleagues like yourself and your colleagues have come up with these descriptions in the International Classification of Headache Disorders). Here again, we're in a “biomarker-free zone,” right? We're really going on the history alone. What are some of the other primary headache disorders that would be management changing here, were you to make a diagnosis of a separate primary headache disorder, as compared to new daily persistent headache? Dr Robbins: I think the two main disorders really are chronic migraine and chronic tension-type headache. Now, what we're taught about chronic migraine and chronic tension-type headache is that they are disorders that begin in their episodic counterparts (episodic migraine, episodic tension-type headache) and then they evolve, over time, to reach or culminate in this daily and continuous headache pattern, typically in the presence of risk factors for that epidemiologic shift we know to exist but that may happen on the individual level, which does include things that we can't modify, like increasing age, women more than men, some social determinants of health (like low socioeconomic status), a head injury (even if it didn't cause a concussion or clear TBI), a stressful life event, medication overuse, having comorbid psychiatric or pain disorders in addition to the headache problem, having sleep apnea that's untreated, and so on. New daily persistent headache - by definition, it should really be kind of “switched on.” Many years ago, Dr Bill Young and Dr. Jerry Swanson wrote an editorial where they labeled new daily persistent headache as the “switched-on headache.” Then, we're taught in headache pathophysiology that this chronification process happens over time because of, perhaps, markers of central sensitization that might clinically express itself as allodynia in trigeminal or extratrigeminal distributions. So, we're not comfortable with this new daily persistent headache, where we think the biology is like chronic migraine that gets switched on abruptly, but in so many patients, it seems to be so - it behaves like chronic migraine otherwise; the comorbidities might be the same; the treatments might still work similarly for both disorders in parallel. So, I think those are the two that we think about. Obviously, if there's unilateral headache, we might think of a trigeminal autonomic cephalalgia that's continuous, even if it doesn't have associated autonomic signs like ptosis or rhinorrhea (which is hemicrania continua) - and in those patients, we would think about a trial of indomethacin. But otherwise, I think chronic migraine and chronic tension-type headache are the two that phenotypically can look like new daily persistent headache. In patients with new daily persistent headache, about half have migraine-type features and about half have tension-type features. When I was a fellow, the International Headache Society and the classification only allowed for those who have more tension-type features to be diagnosed as new daily persistent headache. But we (and many other groups) have found that migraine-type features are very common in people who fulfill rigorously the criteria for new daily persistent headache otherwise. And then the latest iteration of the classification has allowed for us to apply that diagnosis to those with migraine features. Dr Berkowitz: That's very helpful. So, we've ruled out secondary causes and now you're really trying to get into the nuances of the history to determine, did this truly have its abrupt onset or did it evolve from an episodic migraine or tension-type headache? But it could be described by the patient as migrainous, be described by the patient as having tension features The key characteristics (as you mentioned a few times) should be abrupt onset and a continuous nature. Let's say, now you (by history) zeroed in on this diagnosis of new daily persistent headache. You've ruled out potential secondary causes. You're pretty convinced, based on the history, that this is the appropriate primary headache designation. How do you treat these patients? Dr Robbins: Well, that's a great question, Dr Berkowitz, because there's this notoriety to the syndrome that suggests that patients just don't respond to treatments at all. In clinical practice, I can't dispute that to a degree. I think, in general, people who have this syndrome seem to not respond as well, to those who have clear established primary headache disorders. Part of that might be the biology of the disorder; maybe the disorder is turned on by mechanisms that are different to migraine (even though it resembles chronic migraine) and therefore, the medications we know to work for migraine may not be as effective. In some, it could be other factors. There's just a resistance to appreciating that you have this headache disorder that - one day you were normal, the next day you're afflicted by headache that's continuous. And there's almost this nihilism that, “Nothing will work for me, because it's not fair - there's this injustice that I have this continuous headache problem.” And often people with new daily persistent headache may be resistant to, say, behavioral therapies that often are really helpful for migraine or tension-type headache because of this sort of difficult with adjustment to it. But at least there's observational studies that suggest that most of the treatments that work for migraine work for new daily persistent headache. There's been studies that show that people can respond to triptans. In my clinical experience, CGRP antagonists that work for the acute treatment of migraine may work. There is evidence that many of the traditional, older medicines (like tricyclic antidepressants, topiramate, valproate, beta-blockers, probably candesartan) and others that we use for migraine may work. There's observational studies specifically for new daily persistent headache that show that anti-CGRP therapies in the form of monoclonal antibodies and botulinum toxin can work for the disorder. Are there anything specific for some of the new daily persistent headache that might work? Not that we really know. There's been some attempts to say, “Well, if you get these people in the hospital early and try to reduce the risk of headache persistence by giving them DHE, or dexamethasone, or lidocaine, or ketamine, will you reduce the chances of headache persistence at that three-month mark or longer?” We don't really know (there's some people who believe that, though). Maybe there's good reason to do some type of elective hospitalization for aggressive treatment because we know that, notoriously, the treatment response is very mixed. There's been specific treatments that people have looked at. There's been some anecdotes about doxycycline as a broad anti-inflammatory type of treatment that might be used in a variety of neurological disorders, but there's really nothing in the peer-reviewed literature that suggests that is effective or safe, necessarily. And I think a lot of people in new daily persistent headache do develop a profile that resembles chronic migraine (they can develop medication overuse very easily). Often, goal setting is really important in the counseling of such patients. You really have to suggest that the goal for them might be difficult to have them pain-free at zero and cured, but we want this to be treated so the peaks of severity flatten out a bit, and then the baseline level of pain diminishes so that it devolves into a much more episodic disorder over time that looks like regular migraine or regular tension-type headache. Dr Berkowitz: I see. So, in addition to starting a migraine-type prophylactic agent based on the patient's comorbidities and potential benefits of the medication (the same way we would choose a migraine prophylactic), do you do anything, typically, to try to, quote, “break the cycle” - a quick pulse of steroids as an outpatient or a triptan in the office - and see how they do, or do you typically start a prophylactic agent and go from there? Dr Robbins: I think, like all things, it kind of depends on the distress of the patient and how they are functioning. If it's someone who's just out of work, cannot function - and someone like that might be very amenable to an elective hospitalization or some parenteral therapy, or maybe an earlier threshold to use a preventative treatment than we would be doing otherwise in someone with migraine overall - I think that it really depends on that type of a disability that's apparent early. I think it's compelling that, with new daily persistent headache, about a third of people report some antecedent infection that was around at the time. When new daily persistent headache was first described by this Canadian neurologist, Dr Vanast, in the 1980s, it was described in the context of Epstein-Barr virus infection, or at least a higher rate of serologies that are positive for, perhaps, recent Epstein-Barr exposure. And we know that Epstein-Barr is obviously implicated in lots of neurological diseases, like multiple sclerosis. And I mean, I think about these things all the time, and especially with COVID now. So, it's compelling - as a postinfectious disorder, do we, as neurologists (who are so comfortable with using pulse-dose steroids, IVIG) - do we use these things for a new daily persistent headache? But there's no great evidence that enduring inflammation in the dura that would spill into CSF analyses is really present in such patients. There was one study that looked at markers, such as TNF-alpha, in the CSF, but the rates of seeing that were the same in new daily persistent headache and chronic migraine, so there isn't really a specificity to that. Many people we see with new persistent headaches since 2020 may have it as part of a long COVID syndrome (or postacute COVID syndrome), and in those cases, often it's more like “new daily persistent headache-plus.” They might have something that resembles POTS (postural orthostatic tachycardia syndrome); they might have something that resembles fibromyalgia, chronic fatigue. Often in those patients, it takes management of the whole collection of neurological syndromes to get them better, not just the headache alone. Dr Berkowitz: Well, this sounds like such a challenging condition to treat. How do you counsel patients when you've made this diagnosis - what to expect, what the goals are, what this condition is, and how you developed your certainty? It's often challenging (isn't it?) sometimes with patients with headache disorders, when we're not relying on an MRI or lab test to say, “This is the diagnosis”; telling them, it's just our opinion, based on their collection of symptoms and signs. So, how do you give the diagnosis and how do you counsel patients on what it means to them? Dr Robbins: Yeah, it's a great question because it's high stakes, because people will read online, or on social media, or on support groups that this is a dreadful condition - that no one gets better, that they're going to be afflicted with this forever, and the doctors don't know what they're doing, and, “Just don't bother seeing them.” And the truth is not that; there's so many people who can get substantially better. I tell people that it's common; in some epidemiologic studies, one in one thousand people in any given year develop new daily persistent headache, and most of those people get better (they don't seek medical care eventually, or they do, just in the beginning, and then they don't have follow-up because they got all better) - and I think that really happens. I think the people who we see in, say, a headache clinic (or even in general neurology practice) are typically the ones who are the worst of the worst. But even amongst those, we see so many stories of people who get better. So, I really try to reset expectations - like we mentioned before about assessing for treatment response and understanding that improvement will not just mean one day it switches off like it switched on (which seems unfair), but that the spikes will flatten out of pain (first), that the baseline level of intensity will then improve (second); that we turn it into a more manageable day-to-day disorder that really will have less of an impact on someone's quality of life. Sometimes people embrace that and sometimes people have a hard time. But it does require, like many conditions in neurology, incremental care to get people better. Dr Berkowitz: Fantastic. Well, Dr Robbins, thanks so much for taking the time to speak with us today. I've learned so much from your expertise in talking to you and getting to pick your brain about this and some broader concepts and challenges in headache medicine. And I encourage all our listeners to seek out your article on this condition that has even more clinical pearls on how to diagnose and treat patients with this disorder. Dr Robbins: Thanks Dr. Berkowitz - great to be with you. Dr Berkowitz: Again, for our listeners today, I've been interviewing Dr Matthew Robbins, whose article on new daily persistent headache appears in the most recent issue of Continuum, on headache. Be sure to check out other Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr. Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practice. Right now, during our Spring Special, all subscriptions are 15% off. Go to Continpub.com/Spring2024 or use the link in the episode notes to learn more and take advantage of this great discount. This offer ends June 30, 2024. AAN members: go to the link in the episode notes and complete the evaluation to get CME. Thank you for listening to Continuum Audio.

In today's episode, recorded live during San Francisco Climate Week, we delve into the critical intersection of climate policy and carbon removal. Joining us are two distinguished guests:  California Senator Scott Wiener, the author of the recent landmark climate legislation known as California's SB 253 or the Climate Corporate Data Accountability Act, and Shashank Samala, the CEO and Co-founder of Heirloom, a pioneering carbon removal company. Shashank was a previous guest on the show in 2021, and we're excited to have him back to weigh in on this important conversation. Senator Wiener sheds light on the legislative landscape driving climate action, while Shashank offers insights into the  technologies transforming carbon removal. Together, we explore the convergence of policy and innovation, examining how regulatory frameworks catalyze the adoption and scaling of technological solutions. We pack a lot into this conversation, and we hope you enjoy it! In this episode, we cover: [2:15] Senator Scott Wiener's background and personal climate journey[6:04] Shashank's entrepreneurial background and transition to carbon removal[8:38] An overview of Heirloom[10:20] An overview of Scope 1, 2, and 3 emissions[12:59] SB 253, the Climate Corporate Data Accountability Act, authored by Senator Wiener[17:46] California's cap and trade system[20:22] The importance of carbon accounting and measurement, reporting and verification (MRV)[25:32] How the Senator's team worked with startups to verify compliance challenges[31:48] Heirloom's categories of carbon buyers[34:25] SB 308, Carbon Market Development Act, authored by Senator Josh Becker[36:17] The role of geography in carbon removals[40:14] How startups can engage with local policymakers[45:11] The benefit of representing San Francisco as a climate tech hub[46:29] Senator Wiener's wishlist for climate policy, including dense housing and world-class public transportation[47:06] Shashank's wishlist for climate policy, including SB 308 Get connected with MCJ: Jason Jacobs X / LinkedInCody Simms X / LinkedInMCJ Podcast / Collective / YouTube*If you liked this episode, please consider giving us a review! You can also reach us via email at content@mcjcollective.com, where we encourage you to share your feedback on episodes and suggestions for future topics or guests.

InPlanet is an enhanced weathering company spreading rock dust on agricultural fields to draw down CO2. In November, it announced a new investment of $4.6 million from a group of investors. Based in Germany, InPlanet collaborates with farmers in Brazil, aiming to remove 1 million tons of CO2 by 2026. As they work to scale their operations, they face a similar challenge all ERW operations are dealing with right now. While the basic science of rock weathering is well understood, accurately measuring CO2 removal in real-world conditions remains a significant hurdle. Ensuring trust in the process will require improved measurement and verification from what exists today- a problem InPlanet is working to solve.  On this episode we're joined by InPlanet's Head of Carbon Matthew Clarkson who recently released pre-print researchevaluating the different methods of measuring CO2 removal from rock weathering and made recommendations for areas of improvement.  ERW is technologically ready, has co-benefits, and has already attracted significant investment. It is ready to grow to climate relevant scale- but only if it can be properly measured.  On this episode we'll talk with Matthew about his MRV research, working on the ground with Brazilian farmers, and what hurdles he sees to InPlanet's goal of megaton removal in the next three years.  On This Episode Radhika Moolgavkar Mathew Clarkson Resources InPlanet Fundraising News Matthew's Pre-print paper Enhanced Weathering Alliance Bloomberg article on ERW funding Connect with Nori Nori Nori's Twitter Nori's other podcast Reversing Climate Change Nori's CDR meme twitter account --- Send in a voice message: https://podcasters.spotify.com/pod/show/carbonremovalnewsroom/message Support this podcast: https://podcasters.spotify.com/pod/show/carbonremovalnewsroom/support

Pathfinder is shaking things up for the next two weeks with a special pod series on the State of the Space Industry. In each episode, you'll hear from two members of Payload's editorial staff on key trends, exclusive interviews, and insights shaping the industry. This week? Launch & OSAM, featuring Payload's Managing Editor Jacqueline Feldscher and Senior Space Reporter Tim Fernholz. Highlights from the discussion include:LaunchLaunch cadence + increasing demandRole of launch providers and competitionChallenges including space debris and regulationAdvancements in reusabilityOSAMThe OSAM chicken-and-egg problemThe role of government partnerships and regulationsKey technologies required for OSAMRecent developments and upcoming missions, including Northrop Grumman's MRV mission, Astroscale's ADRAS-J mission, and SpaceX's Starship refueling demonstrationsAnd much more…This episode is brought to you by the Italian Trade Agency (ITA). Be sure to check out the Italian Pavilion  in South Hall (Booth 603) during Space Symposium! • Chapters •00:00 - Intro & ITA Ad01:35 - The state of launch in 202304:14 - Peter Beck & Rocket Lab06:31 - Tory Bruno & ULA11:43 - Tim Ellis & Relativity Space14:09 - Make or break in launch15:27 - Government's perspective on launch outside SpaceX17:46 - What Jacqueline is excited for in 202419:07 - Blue Origin & ULA21:41 - Tim Fernholz!22:28 - OSAM. What is it and what companies fall underneath the OSAM umbrella?24:22 - Core capabilities25:19 - OSAM market in 202325:59 - Challenges of building27:10 - Gaps in technology29:53 - Should startups be investing in OSAM technology?32:21 - How integral is the government in developing OSAM?34:13 - Who is setting standards?35:42 - OSAM 137:56 - What Tim is excited for in 2024 • Show notes •Jacqueline's socials — https://twitter.com/jacqfeldscherTim's socials — https://twitter.com/TimFernholzMo's socials — https://twitter.com/itsmoislamPayload's socials — https://twitter.com/payloadspace / https://www.linkedin.com/company/payloadspacePathfinder archive — Watch: https://www.youtube.com/@payloadspace Pathfinder archive — Listen: https://pod.payloadspace.com/episodes • About us •Pathfinder is brought to you by Payload, a modern space media brand built from the ground up for a new age of space exploration and commercialization. We deliver need-to-know news and insights daily to 19,000+ commercial, civil, and military space leaders. Payload is read by decision-makers at every leading new space company, along with c-suite leaders at all of the aerospace & defense primes. We're also read on Capitol Hill, in the Pentagon, and at space agencies around the world.Payload began as a weekly email sent to a few friends and coworkers. Today, we're a team distributed across four time zones and two continents, publishing five media properties across multiple platforms:1) Payload, our flagship daily newsletter, sends M-F @ 9am Eastern2) Pathfinder publishes weekly on Tuesday mornings (pod.payloadspace.com)3) Polaris, our weekly policy briefing, publishes weekly on Tuesdays 4) Payload Research, our weekly research and analysis piece,  comes out on WednesdaysYou can sign up for all of our publications here: https://payloadspace.com/subscribe/

In episode 147, we're excited to welcome Jon Trask, CEO of Dimitra, an AgTech company on a mission to connect smallholder farmers with easy-to-use technology to increase yields, reduce costs, and mitigate risks. We discuss how emerging technologies such as blockchain, AI, and IoT devices, can help smallholder farmers grow their businesses and improve their livelihoods, how blockchain can improve monitoring, reporting, and verification (MRV) by equipping farmers with important data, and much more.--Three Key Takeaways--One of the biggest unlocks of blockchain is ensuring true traceability of products, allowing consumers to see every step of that product's journey from point of harvest to consumption. This will be a gamechanger for socially conscious consumerism and building sustainable supply chains.Blockchain alone won't solve the challenges faced by smallholder farmers and must be leveraged alongside other emerging technologies. In the case of Dimitra, blockchain is built into their platform in conjunction with AI, IoT devices, satellite imaging, genomics, and more.Smallholder farmers are vital to a sustainable and thriving planet. Not only do they play an important role in global food chains but are also vital to local economies and ecosystems. By improving the lives of farmers, it will lead to improved economies and a healthier environment.--Full shownotes with links available at--https://www.cryptoaltruism.org/blog/crypto-altruism-podcast-episode-147-dimitra-empowering-smallholder-farmers-with-ai-blockchain-based-agtech-solutions--Support us with a Fiat or Crypto contribution--Learn more at cryptoaltruism.org/supportus--This episode was recorded on Zencastr!--Interested in starting your own podcast? Use my special link to save 30% off your first month of any Zencastr paid plan. Alternatively, head to zencastr.com/pricing and use my code "CryptoAltruism".Please note: we make use of affiliate marketing to provide readers with referrals to high quality and relevant products and services.--DISCLAIMER --While we may discuss specific web3 projects or cryptocurrencies on this podcast, please do not take any of this as investment advice, and please make sure to do your own research on potential investment opportunities, or any opportunity, before making an investment. We host a variety of guests on this podcast with the sole purpose of highlighting the social impact use cases of this technology. That being said, Crypto Altruism does not endorse any of these projects, and we recognize that, since this is an emerging sector, some may be operating in regulatory grey areas, and as such, we cannot confirm their legality in the jurisdictions in which they operate, especially as it pertains to decentralized finance protocols. So, before getting involved with any project, it's important that you do your own research and confirm the legality of the project. More on the disclaimer at cryptoaltruism.org.

Raviv Turner is a serial big data and AI entrepreneur and the founding member of the Nature Tech Collective, a non-profit coalition of nature tech companies covering satellite imaging, drones, IoT, LIDAR, eDNA, bio-acoustics and other tech that helps financial institutions and corporations measure, report and verify their nature-related impact claims and disclosures, to fight greenwashing and accelerate investment in nature-based solutions. Raviv also sits on the TNFD (Taskforce on Nature-related Financial Disclosures) nature data working group. He speaks on the topics of biodiversity ESG, natural capital, spatial finance, and digital MRV.

Aplicações práticas da Inteligência Artificial no dia a dia de uma das maiores empresas do Brasil, a MRV, líder nos setores de engenharia, construção e incorporação, em destaque nesta semana no Start Eldorado. Entre elas, o uso da IA para avaliação e tomada de decisões na área financeira; o potencial dos dados para conhecer a trajetória de cada cliente e direcionar produtos e ofertas mais aderentes; a apresentação virtualizada de unidades habitacionais; a garantia de segurança na identificação; o mapeamento de tendências de mercado, entre outras. O apresentador Daniel Gonzales conversa com Reinaldo Sima, diretor de Tecnologia e Transformação Digital (CTO) da empresa, que aparece com destaque entre as companhias brasileiras que mais fazem uso de IA. O Start vai ao ar todas as quartas-feiras, às 21h, na Rádio Eldorado FM 107,3 - SP e canais digitais.See omnystudio.com/listener for privacy information.

RP Diet Coach app   RP Hypertrophy App    0:22 Mike isn't sleeping well 2:02 Mike is coming to Australia 3:27 Minimum training to maintain muscle 9:55 Days per week of training vs gains 13:05 How much can you reduce sets by 15:42 Looking deflated vs losing muscle 19:43 Cutting training in half or more 22:06 Beginners can actually gain on very low volume 24:10 MEV, MV, MRV defined 28:35 Systemic MRV defined 31:50 How do you figure out volume landmarks for YOU 36:25 Neural adaptations 39:05 Actually losing muscle 43:40 Stress contributing to muscle loss

Chris Tolles is the CEO and Co-founder of Yard Stick PBC, which stands for Public Benefits Corporation. Yard Stick is aiming to be the measurement backbone for soil carbon. Their handheld hardware enables onsite measurement of soil carbon in agricultural fields, and their software package provides data and analytics that help stakeholders in a soil carbon project to measure and track progress. As Chris tells it, the Yard Stick co-founders got to know one another in the MCJ member community during the pandemic lockdowns in 2020. MCJ is a proud multi-time investor in Yard Stick. Even so, we still learned a ton from Chris during this conversation. Chris highlighted that while MRV technologies are often associated with carbon credit sales, the voluntary carbon market is just one avenue for soil carbon project development. Another that is seeing strong early traction is insetting, where food and agriculture companies are beginning to measure an attempt to reduce the carbon intensity of their own agricultural supply chains. They aren't selling credits; rather, they're starting to make progress on directly reducing the emissions of how their food is grown, which is great news. Chris charts his background and experience and then explains what soil carbon is and why it matters, helping to put the efforts that Yard Stick is making into the context of the broader global carbon cycle. Episode recorded on Oct 13, 2023 (Published on Dec 7, 2023)In this episode, we cover: [02:38]: Chris's background and pivoting from consumer products to climate[08:43]: Origins of Yard Stick in the MCJ Community[11:59]: How Chris and co-founders came to focus on soil organic carbon[14:43]: Cristine Morgan's research background as Yard Stick CSO[18:50]: Overview of soil organic carbon and key drivers of soil carbon stock losses[27:46]: Issues with how claims have been measured historically[33:39]: Why remote sensing technology is insufficient[35:29]: Yard Stick's technology and approach[42:50]: The company's business model[46:00]: Addressing criticism of soil carbon and other nature-based solutions[51:49]: Soil carbon support in Inflation Reduction Act and future policy[56:00]: Yard Stick's $18 million grant from the USDA[58:19]: Their recent $12M Series A round led by Toyota Ventures[01:00:00]: Reckoning with racial injustice and land theft in agriculture[01:02:04]: Encouraging climate companies to address complex social issuesResources mentioned:Demo Carbon Stock Report“Yard Stick lands 10.6M Series A to measure soil carbon” (TechCrunch) Get connected with MCJ: Jason Jacobs X / LinkedInCody Simms X / LinkedInYin Lu X / LinkedInMCJ Podcast / Collective / YouTube*If you liked this episode, please consider giving us a review! You can also reach us via email at content@mcjcollective.com, where we encourage you to share your feedback on episodes and suggestions for future topics or guests.

☕️ No Morning Call de hoje, Henrique Esteter destaca a continuidade dos movimentos favoráveis na abertura dos índices futuros norte-americanos.O petróleo avança, enquanto o minério opera misto a depender do porto.*Dentre os principais destaques: *(i) CVC aumenta ‘take rate' e vendas depois de mudar estratégia;(ii) Elon Musk anuncia o chatbot de IA que será vinculado ao X: Grok;(iii) MRV investe R$ 2 bi no maior projeto da sua história, com 11 mil apartamento.

Not long ago it was difficult to find any information about the carbon removal ecosystem in Europe. Beyond academic papers, and a researcher or two at larger environmental non-profits, CDR policy was not an area with a mature ecosystem. The situation is much different today. Not only is the EU considering ways to incorporate removals into their existing cap-and-trade scheme, but there are non-profits, carbon marketplaces, startups, and a new trade group offering sophisticated information and analysis of the rapidly developing CDR policy landscape in Europe. One of them is Carbon Gap they describe themselves as “a science-based and philanthropy-funded expert non-profit"   NGO working to bring just and equitable carbon removal policies to Europe through informed scientific research. Launched two years ago, the organisation keeps the carbon removal ecosystem informed through its Policy Tracker and regularly publishes articles.” Their most recent piece released last week approaches the thorny topic of avoiding emissions deterrence. Their senior researcher is Kayla Cohen, whose work focuses on the developing soil carbon policies in Europe and climate justice issues. Another organization that continues to provide high-level insight in Europe is Carbonfuture, a marketplace for ‘durable' carbon credits. They claim over 40% of the market for durable carbon removal this year. And luckily for the public they also continue to publish information on the CDR market, including work on the topic of creating a trusted and inclusive MRV system, which we delved into on this show just a few weeks ago. The author of much of this work is their Senior Policy Advisor Sebastian Manhart. The EU is poised to be a world leader in CDR, as it has been with climate policy. It features ambitious climate targets, robust academic research in the field, a talented labor pool, and a sophisticated non-profit sector taking on the challenge. But it also faces many of the headwinds found elsewhere against CDR such as high-costs, ambivalence from some of the public and existing environmental sector, fear of moral hazard, and broader macro-economic challenges threatening investment into newer climate tech. On this episode Kayla and Sebastian join to talk about the current situation in Europe, the developments they'd like to see, and where they predict policy will be in 2030 and beyond.   On This Episode Sebastian Manhart Kayla Cohen Asa Kamer   Resources Carbonfuture Carbon Gap Carbon Gap article on ‘solutions to mitigation deterrence' Our show on Carbonfuture's work on Trust + MRV EU Soil Monitoring Law Sebastian's Article on Incorporating CDR in the ETS Kayla's Article on the EU Soil Monitoring Law Carbonfuture report on CDR law in 31 EU States   Connect with Nori Nori Nori's Twitter Nori's other podcast Reversing Climate Change Nori's CDR meme twitter account --- Send in a voice message: https://podcasters.spotify.com/pod/show/carbonremovalnewsroom/message Support this podcast: https://podcasters.spotify.com/pod/show/carbonremovalnewsroom/support

Carbon removal credits need to be much more trustworthy than carbon offsets are today in order to scale-up CDR. On last week's show, we covered the news that the voluntary carbon markets have shrunk this year. After many carbon offset projects have come under scrutiny, corporate buyers have grown more hesitant. To prove that carbon removal is worth investing in and better than the status quo, project developers and sellers of credits will need to be able to prove that a credit sold actually means CO2 was removed from the air.  It's one thing to do that in a lab when the technique is being developed in a lab. It's another to do it at scale, in the field, in real-world conditions.  The tools available today won't be enough to create market-wide trust. What software, MRV, and accounting technologies are being built today, that will manage the carbon markets of the future? Dr. Anna Lehner at Carbonfuture is one of the people trying to answer this question. Today, we're talking to Anna about how a wide range of CDR methodologies can be measured, quantified, certified, and sold to make it easy for buyers, all while creating more trust in the market.  On This Episode Radhika Moolgavkar Dr. Anna Lehner Resources Carbonfuture Carbonfuture's Trust Framework SBTi Standards cdr.fyi Robert Höglund's post on which companies are buying carbon removal CCS+ Initiative European CRCF Connect with Nori Nori Nori's Twitter Nori's other podcast Reversing Climate Change Nori's CDR meme twitter account   --- Send in a voice message: https://podcasters.spotify.com/pod/show/carbonremovalnewsroom/message Support this podcast: https://podcasters.spotify.com/pod/show/carbonremovalnewsroom/support